Lipid compound, lipid nanoparticle as well as preparation method and application of lipid nanoparticle

By designing lipid compounds with specific structures and combining them with auxiliary materials to form lipid compound nanoparticles, the problems of low biocompatibility and low transfection efficiency of existing liposome nanoparticles have been solved, achieving efficient and low-toxicity nucleic acid delivery.

CN118930449AActive Publication Date: 2024-11-12SHENZHEN LONGUIDE BIOPHARMA CORP
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202410966064.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-12
Estimated Expiration
2044-07-18

AI Technical Summary

Technical Problem

Existing liposome nanoparticles, as non-viral vectors, suffer from poor biocompatibility, low transfection efficiency, poor in vivo delivery, and high toxicity in gene transfection, making it difficult to meet the clinical needs for repeated dosing.

Method used

A lipid compound with a specific structure was designed and combined with auxiliary materials such as PEG derivatives, phospholipids and sterols to form lipid compound nanoparticles for nucleic acid delivery, optimizing its biocompatibility and transfection efficiency.

Benefits of technology

It improves the biocompatibility and transfection efficiency of lipid compound nanoparticles, reduces toxicity, and enhances in vivo delivery, demonstrating excellent technical effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930449A_ABST
    Figure CN118930449A_ABST
Patent Text Reader

Abstract

The invention relates to a lipid compound, and belongs to the technical field of biological medicine and biology. The structure of the lipid compound is shown as a formula A. The lipid compound, the lipid compound nanoparticles or the nucleic acid nanoparticle compound provided by the invention has the advantages of good biocompatibility, high transfection efficiency, high transfection rate, good immunocompetence, good in-vivo delivery effect, low toxicity and the like, and has an excellent technical effect. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and biotechnology, and specifically relates to a lipid compound, lipid nanoparticles, and a preparation method and application thereof. Background Art

[0002] Gene transfection is a technology that transfers or delivers nucleic acids with biological functions into cells and allows the nucleic acids to maintain their biological functions in the cells. Gene vectors refer to a tool that introduces exogenous therapeutic genes into biological cells. Currently, the gene vectors with potential for industrial transformation in the world are mainly viral vectors and non-viral vectors.

[0003] Viral vectors are gene delivery tools that use the ability of viruses to transmit their genomes into other cells for infection. Currently, lentivirus, adenovirus, retrovirus vectors, and adeno-associated virus vectors have good application prospects. However, due to their inherent physical and chemical properties and biological activity, viral vectors have serious disadvantages, such as high production costs, limited loading capacity, poor targeting, insertion integration, teratogenicity, carcinogenicity, and mutagenesis, which are not conducive to the development of universal and general therapies.

[0004] Non-viral vectors mainly include: liposome nanoparticles, composite nanoparticles, cationic polymer nanoparticles, polypeptide nanoparticles, etc. Among them, liposome nanoparticles are the main non-viral vectors currently used in the development of RNA drugs. At present, the first RNAi drug (Patisiran) and the first mRNA drug (BNT162b2, Comirnaty) have been launched one after another, which fully verifies the clinical application value of liposome nanoparticles (LNP). Compared with viral vectors, liposome nanoparticles have the advantages of low production cost, clear chemical structure, easy quality control, targeted drug delivery through targeted modification, and theoretically unlimited encapsulation capacity. However, most liposome lipid materials are non-degradable and highly toxic, so it is difficult to meet the clinical needs of repeated administration. In addition, there are problems such as poor in vivo transfection effect, nucleic acid metabolism or clearance in serum, and low bioavailability.

[0005] Therefore, there is still an urgent need for nanoparticles with good biocompatibility and high transfection efficiency. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides the following technical solutions.

[0007] In a first aspect, the present invention provides a lipid compound.

[0008] (1) A lipid compound, the structure of which is shown in Formula A,

[0009]

[0010] in,

[0011] Each n is independently selected from any positive integer in the range of 1-20 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20), and each m is independently selected from any positive integer in the range of 1-20 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20);

[0012] R 1 , R 2 and R 3 are each independently selected from hydrogen, substituted or unsubstituted C 1-20 Alkyl (the C 1-20 The alkyl group may be a C1 alkyl, a C2 alkyl, a C3 alkyl, a C4 alkyl, a C5 alkyl, a C6 alkyl, a C7 alkyl, a C8 alkyl, a C9 alkyl, a C10 alkyl, a C11 alkyl, a C12 alkyl, a C13 alkyl, a C14 alkyl, a C15 alkyl, a C16 alkyl, a C17 alkyl, a C18 alkyl, a C19 alkyl or a C20 alkyl), a substituted or unsubstituted C 2-20 Alkenyl (the C 2-20 The alkenyl group may be a C2 alkenyl, a C3 alkenyl, a C4 alkenyl, a C5 alkenyl, a C6 alkenyl, a C7 alkenyl, a C8 alkenyl, a C9 alkenyl, a C10 alkenyl, a C11 alkenyl, a C12 alkenyl, a C13 alkenyl, a C14 alkenyl, a C15 alkenyl, a C16 alkenyl, a C17 alkenyl, a C18 alkenyl, a C19 alkenyl or a C20 alkenyl), a substituted or unsubstituted C 2-20 Alkynyl (the C 2-20 The alkynyl group may be a C2 alkynyl, a C3 alkynyl, a C4 alkynyl, a C5 alkynyl, a C6 alkynyl, a C7 alkynyl, a C8 alkynyl, a C9 alkynyl, a C10 alkynyl, a C11 alkynyl, a C12 alkynyl, a C13 alkynyl, a C14 alkynyl, a C15 alkynyl, a C16 alkynyl, a C17 alkynyl, a C18 alkynyl, a C19 alkynyl or a C20 alkynyl), a substituted or unsubstituted C 2-20 Heteroalkyl (the C 2-20 The heteroalkyl group may be C2 heteroalkyl, C3 heteroalkyl, C4 heteroalkyl, C5 heteroalkyl, C6 heteroalkyl, C7 heteroalkyl, C8 heteroalkyl, C9 heteroalkyl, C10 heteroalkyl, C11 heteroalkyl, C12 heteroalkyl, C13 heteroalkyl, C14 heteroalkyl, C15 heteroalkyl, C16 heteroalkyl, C17 heteroalkyl, C18 heteroalkyl, C19 heteroalkyl or C20 heteroalkyl),

[0013]

[0014] wherein the substituted or unsubstituted C 1-20 Alkyl, substituted or unsubstituted C 2-20Alkenyl, substituted or unsubstituted C 2-20 Alkynyl or substituted or unsubstituted C 2-20 The substitution in heteroalkyl independently means that at least one hydrogen atom is replaced by 1-5 halogen, cyano, -OR 4 、-SR 4 、N(R 4 )2、-N(R 4 )3 + , oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C 1-6 substituted with haloalkyl;

[0015] Each R 4 are independently selected from hydrogen, substituted or unsubstituted C 1-12 Alkyl (the C 1-12 The alkyl group may be a C1 alkyl group, a C2 alkyl group, a C3 alkyl group, a C4 alkyl group, a C5 alkyl group, a C6 alkyl group, a C7 alkyl group, a C8 alkyl group, a C9 alkyl group, a C10 alkyl group, a C11 alkyl group or a C12 alkyl group), a substituted or unsubstituted C 2-12 Alkenyl (the C 2-12 The alkenyl group may be a C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl, C6 alkenyl, C7 alkenyl, C8 alkenyl, C9 alkenyl, C10 alkenyl, C11 alkenyl or C12 alkenyl) or a substituted or unsubstituted C 2-12 Alkynyl (the C 2-12 The alkynyl group may be a C2 alkynyl, C3 alkynyl, C4 alkynyl, C5 alkynyl, C6 alkynyl, C7 alkynyl, C8 alkynyl, C9 alkynyl, C10 alkynyl, C11 alkynyl or C12 alkynyl group); wherein each R 4 Each substituted or unsubstituted C 1-12 Alkyl, substituted or unsubstituted C 2-12 Alkenyl or substituted or unsubstituted C 2-12 Substitution in the alkynyl group independently means that at least one hydrogen atom is replaced by 1 to 5 halogen, cyano, -OH, -SR 5 、N(R 5 )2 or -N(R 5 )3 + or at least 2 hydrogen atoms are replaced by =O;

[0016] Each R 5 are independently selected from hydrogen, substituted or unsubstituted C 1-12 Alkyl (the C 1-12 The alkyl group may be a C1 alkyl group, a C2 alkyl group, a C3 alkyl group, a C4 alkyl group, a C5 alkyl group, a C6 alkyl group, a C7 alkyl group, a C8 alkyl group, a C9 alkyl group, a C10 alkyl group, a C11 alkyl group or a C12 alkyl group), a substituted or unsubstituted C 2-12Alkenyl (the C 2-12 The alkenyl group may be a C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl, C6 alkenyl, C7 alkenyl, C8 alkenyl, C9 alkenyl, C10 alkenyl, C11 alkenyl or C12 alkenyl) or a substituted or unsubstituted C 2-12 Alkynyl (the C 2-12 The alkynyl group may be a C2 alkynyl, C3 alkynyl, C4 alkynyl, C5 alkynyl, C6 alkynyl, C7 alkynyl, C8 alkynyl, C9 alkynyl, C10 alkynyl, C11 alkynyl or C12 alkynyl group); wherein each R 5 Each substituted or unsubstituted C 1-12 Alkyl, substituted or unsubstituted C 2-12 Alkenyl or substituted or unsubstituted C 2-12 Substitution in the alkynyl group independently means that at least one hydrogen atom is replaced by 1 to 5 halogen, cyano, -OH, -SH, NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + or at least an even number of hydrogen atoms are replaced by =O;

[0017] Each L is independently selected from C 1-10 Alkylene (the C 1-10 The alkylene group may be C1 alkylene, C2 alkylene, C3 alkylene, C4 alkylene, C5 alkylene, C6 alkylene, C7 alkylene, C8 alkylene, C9 alkylene, C10 alkylene, C11 alkylene or C12 alkylene) or C 3-10 Heteroalkylene (the C 3-10 The heteroalkylene group may be a C3 heteroalkylene group, a C4 heteroalkylene group, a C5 heteroalkylene group, a C6 heteroalkylene group, a C7 heteroalkylene group, a C8 heteroalkylene group, a C9 heteroalkylene group, a C10 heteroalkylene group, a C11 heteroalkylene group, or a C12 heteroalkylene group);

[0018] Each Y is independently selected from -O- or -NR 6 -;

[0019] Each R 6 are independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl (the C 1-6 The alkyl group may be a C1 alkyl group, a C2 alkyl group, a C3 alkyl group, a C4 alkyl group, a C5 alkyl group or a C6 alkyl group), a substituted or unsubstituted C 2-6 Alkenyl (the C 2-6 The alkenyl group may be a C2 alkenyl group, a C3 alkenyl group, a C4 alkenyl group, a C5 alkenyl group or a C6 alkenyl group), a substituted or unsubstituted C 2-6 Alkynyl (the C 2-6The alkynyl group may be a C2 alkynyl group, a C3 alkynyl group, a C4 alkynyl group, a C5 alkynyl group or a C6 alkynyl group) or a substituted or unsubstituted C 1-6 haloalkyl; wherein each R 6 Each substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl or substituted or unsubstituted C 1-6 The substitution in haloalkyl independently means that at least one hydrogen atom is replaced by 1-5 halogen, cyano, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + , C 1-6 Alkoxy or C 1-6 or at least 2 hydrogen atoms are replaced by =O;

[0020] Each R is independently selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 2-20 Alkynyl, -Z 1 -heterocyclic group, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkynyl, -Z 1 -C 1-6 Alkylene-Z-heterocyclyl, -Z 1 -C 2-6 Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 Alkenyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 Alkynyl, -Z 1 -C 2-6 Alkynyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkynyl-ZC 2-20 Alkenyl or -Z 1 -C 2-6 Alkynyl-ZC2-20 Alkynyl (the C in each R 1-20 The alkyl group may be independently selected from C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl, C7 alkyl, C8 alkyl, C9 alkyl, C10 alkyl, C11 alkyl, C12 alkyl, C13 alkyl, C14 alkyl, C15 alkyl, C16 alkyl, C17 alkyl, C18 alkyl, C19 alkyl or C20 alkyl; the C in each R 2-20 The alkenyl groups are independently selected from C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl, C6 alkenyl, C7 alkenyl, C8 alkenyl, C9 alkenyl, C10 alkenyl, C11 alkenyl, C12 alkenyl, C13 alkenyl, C14 alkenyl, C15 alkenyl, C16 alkenyl, C17 alkenyl, C18 alkenyl, C19 alkenyl or C20 alkenyl; the C in each R 2-20 The alkynyl group may be a C2 alkynyl, C3 alkynyl, C4 alkynyl, C5 alkynyl, C6 alkynyl, C7 alkynyl, C8 alkynyl, C9 alkynyl, C10 alkynyl, C11 alkynyl, C12 alkynyl, C13 alkynyl, C14 alkynyl, C15 alkynyl, C16 alkynyl, C17 alkynyl, C18 alkynyl, C19 alkynyl or C20 alkynyl; the C in each R 1-6 The alkyl group may be a C1 alkyl group, a C2 alkyl group, a C3 alkyl group, a C4 alkyl group, a C5 alkyl group or a C6 alkyl group; the C 1-6 The alkylene group may be independently selected from C1 alkylene, C2 alkylene, C3 alkylene, C4 alkylene, C5 alkylene or C6 alkylene; the C in each R 2-6 The alkenyl group may be independently selected from C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl or C6 alkenyl; the C in each R 2-6 The alkynyl groups may be independently selected from C2 alkynyl, C3 alkynyl, C4 alkynyl, C5 alkynyl or C6 alkynyl);

[0021] Each Z is independently selected from a carbon-carbon single bond, -O-, -O-CH2-O-, -O-CH2(CH3)-O-, -OC(O)-, -NR 4 C(O)-, -C(O)O-, -NR 4 -, -S-, -SS-, -C(O)-, -C(O)NR 4 -、-S(O)-、-S(O)2-、-NR 4 C(O)O-、-NR 4 C(O)NR 4 -、-NR 4 S(O)- or -S(O)2NR 4 -;

[0022] Each Z 1are independently selected from carbon-carbon single bonds, -O-, -NR 4 -, -S-, -SS-, -C(O)-, -C(O)O-, -C(O)NR 4 -、-S(O)-、-S(O)2-、-NR 4 C(O)-、-NR 4 C(O)O-、-NR 4 C(O)NR 4 -、-NR 4 S(O)- or -S(O)2NR 4 -;

[0023] Each R 4 are independently selected from H or C 1-6 alkyl;

[0024] In the compound represented by formula A, each The linear moiety contains at least 6 linear atoms or contains 6-20 linear atoms.

[0025] In some embodiments, the C 2-20 The heteroalkyl group contains at least one heteroatom, and the heteroatom includes at least one of N, S or O.

[0026] In some embodiments, in the compound represented by formula A, each The moiety may contain at least 6 linear atoms or 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 linear atoms.

[0027] (2) In any of the lipid compounds described in (1), R 1 , R 2 and R 3 are independently selected from hydrogen, substituted or unsubstituted C 1-20 alkyl,

[0028] Each R 6 are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl;

[0029] Each R is independently selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1-C 2-6 Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 Alkenyl.

[0030] (3) In the lipid compound described in any one of (1) or (2), n is selected from any positive integer from 1 to 20, and m is selected from any positive integer from 1 to 20;

[0031] R 1 , R 2 and R 3 are independently selected from hydrogen, unsubstituted C 1-20 Alkyl or

[0032] R 6 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl;

[0033] Each Y is independently selected from -O- or -NR 6 -;

[0034] R is selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1 -C 2-6 Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 alkenyl;

[0035] Each Z is independently selected from a carbon-carbon single bond, -O-, -O-CH2-O-, -O-CH2(CH3)-O-, -OC(O)-, -NR 4 C(O)-, -C(O)O-;

[0036] Each Z 1 Independently selected from -O-, -NR 4 -;

[0037] Each R 4 are independently selected from H or C 1-6 alkyl.

[0038] (4) In any one of the lipid compounds described in (1) to (3), the compound represented by formula A includes compound B,

[0039]

[0040] (5) In any one of the lipid compounds described in (1) to (4), the compound represented by formula B includes: compound C, compound D,

[0041]

[0042] (6) In any of the lipid compounds described in (1) to (5), in the compound C, n is selected from any positive integer from 1 to 10 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), m is selected from any positive integer from 1 to 20 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20); R is selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1 -C 2-6 Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 Alkenyl (the C in each R 1-20 The alkyl group may be independently selected from C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl, C7 alkyl, C8 alkyl, C9 alkyl, C10 alkyl, C11 alkyl, C12 alkyl, C13 alkyl, C14 alkyl, C15 alkyl, C16 alkyl, C17 alkyl, C18 alkyl, C19 alkyl or C20 alkyl; the C in each R 2-20 The alkenyl groups are independently selected from C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl, C6 alkenyl, C7 alkenyl, C8 alkenyl, C9 alkenyl, C10 alkenyl, C11 alkenyl, C12 alkenyl, C13 alkenyl, C14 alkenyl, C15 alkenyl, C16 alkenyl, C17 alkenyl, C18 alkenyl, C19 alkenyl or C20 alkenyl; the C in each R 2-20The alkynyl group may be a C2 alkynyl, C3 alkynyl, C4 alkynyl, C5 alkynyl, C6 alkynyl, C7 alkynyl, C8 alkynyl, C9 alkynyl, C10 alkynyl, C11 alkynyl, C12 alkynyl, C13 alkynyl, C14 alkynyl, C15 alkynyl, C16 alkynyl, C17 alkynyl, C18 alkynyl, C19 alkynyl or C20 alkynyl; the C in each R 1-6 The alkyl group may be a C1 alkyl group, a C2 alkyl group, a C3 alkyl group, a C4 alkyl group, a C5 alkyl group or a C6 alkyl group; the C 1-6 The alkylene group may be independently selected from C1 alkylene, C2 alkylene, C3 alkylene, C4 alkylene, C5 alkylene or C6 alkylene; the C in each R 2-6 The alkenyl group may be independently selected from C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl or C6 alkenyl; the C in each R 2-6 The alkynyl groups may be independently selected from C2 alkynyl, C3 alkynyl, C4 alkynyl, C5 alkynyl or C6 alkynyl);

[0043] In the compound C, each Z is independently selected from a carbon-carbon single bond, -O-, -O-CH2-O-, -O-CH2(CH3)-O-, -OC(O)-, -NR 4 C(O)-, -C(O)O-;

[0044] In the compound C, each Z 1 Independently selected from -O-, -NR 4 -;

[0045] In the compound C, each R 4 are independently selected from H or C 1-6 alkyl;

[0046] In the compound D, R 6 is selected from hydrogen or unsubstituted C 1-3 Alkyl; n is selected from any positive integer in 1-10 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10), m is selected from any positive integer in 1-20 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20); R is selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1 -C 2-6Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 Alkenyl (the C in each R 1-20 The alkyl group may be independently selected from C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl, C7 alkyl, C8 alkyl, C9 alkyl, C10 alkyl, C11 alkyl, C12 alkyl, C13 alkyl, C14 alkyl, C15 alkyl, C16 alkyl, C17 alkyl, C18 alkyl, C19 alkyl or C20 alkyl; the C in each R 2-20 The alkenyl groups are independently selected from C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl, C6 alkenyl, C7 alkenyl, C8 alkenyl, C9 alkenyl, C10 alkenyl, C11 alkenyl, C12 alkenyl, C13 alkenyl, C14 alkenyl, C15 alkenyl, C16 alkenyl, C17 alkenyl, C18 alkenyl, C19 alkenyl or C20 alkenyl; the C in each R 2-20 The alkynyl group may be a C2 alkynyl, C3 alkynyl, C4 alkynyl, C5 alkynyl, C6 alkynyl, C7 alkynyl, C8 alkynyl, C9 alkynyl, C10 alkynyl, C11 alkynyl, C12 alkynyl, C13 alkynyl, C14 alkynyl, C15 alkynyl, C16 alkynyl, C17 alkynyl, C18 alkynyl, C19 alkynyl or C20 alkynyl; the C in each R 1-6 The alkyl group may be a C1 alkyl group, a C2 alkyl group, a C3 alkyl group, a C4 alkyl group, a C5 alkyl group or a C6 alkyl group; the C 1-6 The alkylene group may be independently selected from C1 alkylene, C2 alkylene, C3 alkylene, C4 alkylene, C5 alkylene or C6 alkylene; the C in each R 2-6 The alkenyl group may be independently selected from C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl or C6 alkenyl; the C in each R 2-6 The alkynyl groups may be independently selected from C2 alkynyl, C3 alkynyl, C4 alkynyl, C5 alkynyl or C6 alkynyl);

[0047] In the compound D, each Z is independently selected from a carbon-carbon single bond, -O-, -O-CH2-O-, -O-CH2(CH3)-O-, -OC(O)-, -NR 4 C(O)-, -C(O)O-;

[0048] In the compound D, each Z 1 Independently selected from -O-, -NR 4 -;

[0049] In the compound D, each R 4 are independently selected from H or C 1-6 alkyl.

[0050] In some embodiments, the halogen includes at least one of F, Cl, Br, and I.

[0051] (7) In any of the lipid compounds described in (1) to (6), the compound C is selected from compound L0461, compound L0464, compound L0465, compound L0467, compound L0468, compound L0469, compound L0470, compound L0471, compound L0472, compound L0475, compound L0476, compound L0477, compound L0478, compound L0479, compound L0491, compound L0492, compound L0497, and compound L0498;

[0052] The compound D is selected from the group consisting of compounds L0462, L0463, L0473, L0474, L0480, L0481, L0482, L0483, L0484, L0485, L0486, L0487, L0488, L0489, L0490, L0493, L0494, L0495, L0496, L0499, L0500, L0501, L0502, L0503, L0504, L0505, and L0506;

[0053]

[0054]

[0055]

[0056]

[0057]

[0058]

[0059]

[0060]

[0061]

[0062] In a second aspect, the present invention provides a lipid compound nanoparticle.

[0063] (8) The present invention provides the following lipid compound nanoparticles.

[0064] A lipid compound nanoparticle, comprising the lipid compound described in the first aspect and auxiliary materials; or comprising the lipid compound described in the first aspect, nucleic acid and auxiliary materials.

[0065] In some embodiments, the auxiliary material is selected from at least one of: PEG derivatives, lipids, lipidoids, alcohols, sugars or inorganic salts.

[0066] In some embodiments, the PEG derivative is selected from at least one of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, PEG-modified stearic acid, and PEG-modified phosphatidylserine.

[0067] In some embodiments, the PEG derivative includes 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)], dilauroylphosphatidylethanolamine-polyethylene glycol, dimyristoylphosphatidylethanolamine-polyethylene glycol, dipalmitoylphosphatidylcholine polyethylene glycol, dipalmitoylphosphatidylethanolamine-polyethylene glycol, PEG-distearylglycerol, PEG-dipalmitoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglyceramide, PEG-dipalmitoylphosphatidylethanolamine or PEG-1,2-dimyristyloxypropyl-3-amine.

[0068] In some embodiments, the PEG derivative includes at least one of DMG-PEG2000, mPEG-DSPE, mPEG-STA, mPEG-PS, mPEG-DMPE, mPEG-DPPE, ALC-0159, mPEG2k-DMPE, and DSPE-PEG5000.

[0069] In some embodiments, the lipid comprises a lipid selected from a phospholipid or a sterol.

[0070] In some embodiments, the phospholipid includes at least one selected from phospholipids, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-diondecanoyl-sn-glycero-phosphocholine, and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.

[0071] In some embodiments, the sterol comprises at least one of cholesterol, lanosterol, 5α-cholestane-3β-ol, coprostanol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid, or α-tocopherol.

[0072] (9) In the lipid compound nanoparticles described in (8), the lipid compound nanoparticles further include the following components.

[0073] In some embodiments, in the lipid compound nanoparticles described in (8), the lipid compound nanoparticles include the lipid compound described in the first aspect and auxiliary materials; or include the lipid compound described in the first aspect, nucleic acid and auxiliary materials;

[0074] The auxiliary materials are PEG derivatives and lipids; the lipids are selected from phospholipids or sterols.

[0075] In some embodiments, the phospholipid includes at least one selected from phosphatidylcholine (PC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diondecanoyl-sn-glycero-phosphocholine, and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.

[0076] In some embodiments, the sterol comprises at least one of cholesterol, lanosterol, 5α-cholestane-3β-ol, coprostanol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid, or α-tocopherol.

[0077] (10) The lipid compound nanoparticles described in any one of (8) to (9), further comprising:

[0078] In some embodiments, in the lipid compound nanoparticles described in any one of (8)-(9), the content of the lipid compound described in the first aspect is 20.0 mol%-75.0 mol%, calculated based on the total molar amount of each component in the lipid compound nanoparticles.

[0079] In some embodiments, the content of the PEG derivative is 0.5 mol%-10 mol%, calculated based on the total molar amount of each component in the lipid compound nanoparticles.

[0080] In some embodiments, the content of the phospholipid is 4.0 mol%-20.0 mol%, calculated based on the total molar amount of each component in the lipid compound nanoparticles.

[0081] In some embodiments, the content of the sterol is 18.0 mol%-68.5 mol% based on the total molar amount of each component in the lipid compound nanoparticle. In some embodiments, the content of the sterol is 20.0 mol%-68.5 mol% based on the total molar amount of each component in the lipid compound nanoparticle.

[0082] In some embodiments, the molar ratio of PEG derivative: phospholipid: sterol: lipid compound of the first aspect in the lipid compound nanoparticles is (0.5-10.0): (4.0-20.0): (18.0-68.5): (20.0-75.0).

[0083] In some embodiments, the molar ratio of PEG derivative: phospholipid: sterol: lipid compound of the first aspect in the lipid compound nanoparticles is (0.5-10.0):(4.0-20.0):(20.0-68.5):(20.0-75.0).

[0084] In some embodiments, the molar ratio of the PEG derivative:phospholipid:sterol:lipid compound of the first aspect in the lipid compound nanoparticles is 2.50:16.00:33.00:48.50, 6.00:16.00:29.50:48.50, 2.50:4.00:45.00:48.50, 0.95:7.58:26.47:65.00, 1.50:11.50:38.50:48.50, 1.58:16.84:18.42:63.16, 10.00:4.00:56.00:30.00, 2.32:6.20:45.00:46.4 8. 0.50:4.00:65.50:30.00, 2.50:11.50:56.00:30.00, 2.00:5.00:68.00:25.00, 3.00:4.00:18.00:75.00, 2.00:20.00:43.00:35.00, 1.50:10.00:68.50:20.00, 2.50:4.00:63.50:30.00, 1.50:16.00:22.50:60.00, 1.50:4.00:64.50:30.00 or 1.40:11.15:38.95:48.50.

[0085] In some embodiments, the molar ratio of PEG derivative: phospholipid: sterol: lipid compound of the first aspect in the lipid compound nanoparticles is (0.5-2.5): (7.58-16.0): (29.5-56.0): (35.0-48.5).

[0086] In some embodiments, the molar ratio of PEG derivative: phospholipid: sterol: lipid compound of the first aspect in the lipid compound nanoparticles is 0.50:4.00:65.50:30.00, 1.50:11.50:38.50:48.50 or 1.40:11.15:38.95:48.50.

[0087] In some embodiments, the PEG derivative is DMG-PEG2000 (also known as DMG-PEG2k), mPEG-DMPE, mPEG-DSPE, ALC-0159, mPEG-DPPE, mPEG-STA, mPEG-PS, mPEG2k-DMPE, DSPE-PEG5000.

[0088] In some embodiments, the phospholipid includes at least one of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), phosphatidylcholine (PC), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

[0089] In some embodiments, the sterol includes at least one of cholesterol (Chol) and lanosterol (Lanosterol).

[0090] In a third aspect, the present invention provides a nucleic acid-nanoparticle complex.

[0091] (11) A nucleic acid-nanoparticle complex comprising a nucleic acid and the lipid compound nanoparticles described in the second aspect.

[0092] In some embodiments, the ratio of the molar amount of ionizable nitrogen atoms in the compound in the lipid compound nanoparticles of the second aspect to the molar amount of phosphorus atoms in the nucleic acid (ie, nitrogen-phosphorus ratio) in the nucleic acid-nanoparticle complex is 6-65.

[0093] In some embodiments, the ratio of the molar amount of ionizable nitrogen atoms in the lipid compound in the lipid compound nanoparticles of the second aspect to the molar amount of phosphorus atoms in the nucleic acid in the nucleic acid nanoparticle complex is 6, 7, 8, 9, 10, 11, 12, 13, 13.5, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 or 65.

[0094] In some embodiments, the nucleic acid is deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

[0095] In some embodiments, the ribonucleic acid (RNA) includes at least one of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), self-replicating RNA (saRNA), small hairpin RNA (shRNA), circular RNA (circRNA), messenger RNA (mRNA), or a combination thereof.

[0096] In some embodiments, the average particle size of the lipid compound complex is 70nm-300nm. In some embodiments, the average particle size of the lipid compound complex is 70nm-270nm. In some embodiments, the average particle size of the lipid compound complex is 70nm-268nm. In some embodiments, the average particle size of the lipid compound complex is 70nm, 75nm, 80nm, 85nm

[0097] , 90nm, 95nm, 100nm, 105nm, 110nm, 115nm, 120nm, 125nm, 130nm, 135nm, 140nm, 145nm, 150nm, 155nm, 160nm, 165nm, 170nm, 175nm, 180nm, 185nm, 190nm, 195nm, 200nm, 205nm, 210nm, 215nm, 220nm, 225nm, 230nm, 235nm, 240nm, 245nm, 250nm, 255nm, 260nm, 265nm, 268nm, 270nm, 275nm, 280nm, 285nm, 290nm, 295nm or 300nm.

[0098] In some embodiments, the lipid compound complex has a polydispersity coefficient of ≤ 0.30.

[0099] In some embodiments, the nucleic acid nanoparticle complex is a nucleic acid nanoparticle complex selected from any of the following numbers:

[0100]

[0101]

[0102]

[0103]

[0104]

[0105] In a fourth aspect, the present invention provides a pharmaceutical composition.

[0106] (12) A pharmaceutical composition.

[0107] In some embodiments, a pharmaceutical composition comprises the lipid compound nanoparticles of the second aspect or the nucleic acid nanoparticle complexes of the third aspect, and a pharmaceutically acceptable excipient.

[0108] In some embodiments, the dosage form of the pharmaceutical composition includes injection, suppository, eye drops, tablets, capsules, suspensions or inhalants.

[0109] In a fifth aspect, the present invention provides a use.

[0110] (13) Use of the lipid compound of the first aspect, the lipid compound nanoparticle of the second aspect, the nucleic acid nanoparticle complex of the third aspect, or the pharmaceutical composition of the fourth aspect in the preparation of a product for in vivo delivery of nucleic acids.

[0111] Beneficial Effects

[0112] Compared with the prior art, the present invention has at least one of the following technical effects:

[0113] The lipid compound, lipid compound nanoparticle or nucleic acid nanoparticle complex provided by the present invention has the advantages of good biocompatibility, high transfection efficiency, high transfection rate, good immune activity, good in vivo delivery effect, low toxicity, etc., and has excellent technical effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0114] Figure 1 The statistical graph of serum IgG antibody levels of mice immunized with the nucleic acid nanocomplex loaded with SARS-CoV-2 S-mRNA in Example 8 is shown;

[0115] Figure 2 The statistical graph of serum IgG antibody titers of mice after immunization with the nucleic acid nanocomplex loaded with SARS-CoV-2 S-mRNA in Example 8 is shown.

[0116] Definition of terms

[0117] Unless otherwise indicated, the following terms and phrases as used herein are intended to have the following meanings:

[0118] In the present invention, expressions such as "L0461", "compound L0461" and "compound represented by formula L0461" refer to the same compound.

[0119] "V / V" or "v / v" means volume ratio.

[0120] The terms "plurality" or "several" mean at least 2, for example 2, 3, 4 or 5, etc.

[0121] The term "and / or" should be understood to mean any one of the optional items or a combination of any two or more of the optional items.

[0122] “Any positive integer selected from 1-20” means 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0123] “Any positive integer selected from 1-10” means 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0124] The term "mol%" means molar percentage.

[0125] The term "optional", "optional" or "optionally" means that the event or situation described later may but does not necessarily occur. For example, "optionally, the heteroatom in the heterocycle includes at least one selected from nitrogen, oxygen, and sulfur" means that the situation of "the heteroatom in the heterocycle includes at least one selected from nitrogen, oxygen, and sulfur" may exist or not exist.

[0126] In the present invention, "room temperature" refers to ambient temperature, which is from about 10°C to about 40°C. In some embodiments, "room temperature" refers to a temperature from about 20°C to about 30°C; in other embodiments, "room temperature" refers to a temperature from about 25°C to about 30°C; in still other embodiments, "room temperature" refers to 10°C, 15°C, 20°C, 25°C, 30°C, 35°C, 40°C, etc.

[0127] "Alkyl" is a hydrocarbon containing positive carbon atoms, secondary carbon atoms, tertiary carbon atoms, or cyclic carbon atoms. For example, an alkyl group can have 1 to 20 carbon atoms (i.e., C1-C 20alkyl), 1 to -8 carbon atoms (i.e., C1-C8 alkyl) or 1 to -6 carbon atoms (i.e., C1-C6 alkyl). Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (i-Pr, i-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH (CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl ( -CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH (CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3 or octyl (-(CH2)7CH3).

[0128] The term "alkylene" means a saturated divalent hydrocarbon radical obtained by removing two hydrogen atoms from a saturated straight or branched hydrocarbon radical. Unless otherwise specified, an alkylene group contains 1-12 carbon atoms. In one embodiment, an alkylene group contains 1-6 carbon atoms; in another embodiment, an alkylene group contains 1-4 carbon atoms; in yet another embodiment, an alkylene group contains 1-3 carbon atoms; in yet another embodiment, an alkylene group contains 1-2 carbon atoms. Such examples include methylene (-CH2-), ethylene (-CH2CH2-), isopropylene (-CH(CH3)CH2-), and the like. The alkylene group is optionally substituted with one or more substituents described herein.

[0129] The term "carbocyclyl" or "carbocycle" refers to a monovalent or polyvalent non-aromatic saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing 3-12 carbon atoms. Bicyclic or tricyclic ring systems may include fused rings, bridged rings and spirocyclic rings. Carbobicyclic groups include spirocarbobicyclic groups and fused carbobicyclic groups. Suitable carbocyclyl groups include, but are not limited to, cycloalkyl, cycloalkenyl and cycloalkynyl groups. In one embodiment, the carbocyclyl contains 3-10 carbon atoms, such as C 3- C 10 In another embodiment, the carbocyclic group contains 3-8 carbon atoms, such as C 3- C8 carbocyclyl; In another embodiment, the carbocyclyl contains 3-6 carbon atoms, such as C 3- In another embodiment, the monocyclic carbocyclic group contains 4-8 carbon atoms, such as C 4- C8 monocyclic carbocyclic group; In another embodiment, the monocyclic carbocyclic group contains 4-6 carbon atoms, such as C 4-C6 monocyclic carbocyclic radical.The example of carbocyclic radical group further comprises, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-1-alkenyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, etc.Described carbocyclic radical group is optionally substituted by one or more substituents described in the present invention. The example of carbocyclyl group further includes, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-1-alkenyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, etc.When the structure clearly needs a linking group, the Markush variable listed for the group should be understood as a linking group.For example, if the structure needs a linking group and the Markush group definition for the variable lists "carbocyclyl", it should be understood that the subcarbocyclyl group connected by the "carbocyclyl" representative.

[0130] The term "cycloalkyl" refers to a monovalent or polyvalent saturated monocyclic, bicyclic or tricyclic ring system containing 3 to 12 carbon atoms. The bicyclic or tricyclic ring system may include fused rings, bridged rings and spiro rings. In one embodiment, the cycloalkyl contains 3 to 10 carbon atoms, such as C 3- C 10 In another embodiment, the cycloalkyl group contains 3-8 carbon atoms, such as C 3- C8 cycloalkyl; In another embodiment, the cycloalkyl contains 3-6 carbon atoms, such as C 3- C6 cycloalkyl. The cycloalkyl groups may independently be unsubstituted or substituted with one or more substituents described herein.

[0131] The term "alkoxy" means an alkyl group attached to the rest of the molecule via an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In one embodiment, the alkoxy group contains 1-6 carbon atoms; in another embodiment, the alkoxy group contains 1-4 carbon atoms; in yet another embodiment, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents as described herein.

[0132] Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-1-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC(CH3)3), and the like.

[0133] An "alkenyl group" is a group containing at least one unsaturated site, i.e., a carbon-carbon sp 2 For example, an alkenyl group can have 2 to 10 carbon atoms (C2-C 10 alkenyl), 2 to 12 carbon atoms (C2-C 12 The alkenyl group may be optionally substituted with one or more substituents as described herein, including "cis" and "trans" orientations, or "E" and "Z" orientations. Examples of suitable alkenyl groups include, but are not limited to, ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-C5H7) 5-hexenyl (-CH2CH2CH2CH2CH=CH2).

[0134] "Alkynyl" is a hydrocarbon containing a positive carbon atom, a secondary carbon atom, a tertiary carbon atom or a ring carbon atom having at least one unsaturated site, i.e., a carbon-carbon sp triple bond. The alkynyl group may be optionally substituted with one or more substituents described herein. For example, an alkynyl group may have 2 to 10 carbon atoms (C2-C 10 Alkynyl), 2 to 12 carbon atoms (C2-C 12 Examples of suitable alkynyl groups include, but are not limited to, ethynyl (-C=CH), propargyl (-CH2C=CH), or the like.

[0135] The term "aryl" refers to a monocyclic, bicyclic and tricyclic carbon ring system containing 6-20 ring atoms, or 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic, wherein each ring system comprises a ring consisting of 3-7 atoms. The aryl group is usually, but not necessarily, connected to the parent molecule through the aromatic ring of the aryl group. The term "aryl" can be used interchangeably with the term "aromatic ring" or "aromatic ring". Examples of aryl groups can include groups derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like. The aryl group is optionally substituted by one or more substituents described herein.

[0136] "Arylalkyl" refers to a radical in which the 3 The term "arylalkyl" refers to an alkyl radical having a carbon atom (carbon atom) and a cycloalkyl radical having a carbon atom (carbon atom). The term "arylalkyl" refers to an alkyl radical having a carbon atom (carbon atom) and a cycloalkyl radical having a carbon atom (carbon atom). Typical arylalkyl includes, but is not limited to, benzyl, 2-phenyl second-1-yl, naphthylmethyl, 2-naphthyl second-1-yl, naphthobenzyl, 2-naphthophenyl second-1-yl and analogue. Arylalkyl can comprise 7 to 20 carbon atoms, for example, alkyl moiety is 1 to 6 carbon atom, and aryl moiety is 6 to 14 carbon atoms.

[0137] The term "substituted" refers to alkyl, aryl, arylalkyl, heterocyclyl, heteroaryl, carbocyclyl, etc., for example, "substituted C1-C 10 Alkyl", "substituted C6-C 20 Aryl", "substituted arylalkyl", "substituted C1-C 20 "Heterocycle" and "substituted carbocyclyl" refer to C1-C2-1, C1-C3-1, C1-C4-1, C1-C6-1, C1-C7-1, C1-C8-1, C1-C9-1, C1-C1 ... 10 Alkyl, C6-C 20 Aryl, Arylalkyl, C1-C 20 Heterocycle, alkylamino, carbocyclyl. Unless otherwise indicated, when the term "substituted" is used in conjunction with a group having two or more moieties capable of substitution, such as arylalkyl, the substituents may be attached to the aryl portion, the alkyl portion, or both.

[0138] The term "alkylamino" or "alkylamino" includes "N-alkylamino" and "N,N-dialkylamino", wherein the amino group is independently substituted with one or two alkyl groups, wherein the alkyl group has the meaning as described herein. Suitable alkylamino groups can be monoalkylamino or dialkylamino, such examples include, but are not limited to, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino and the like. The alkylamino group is optionally substituted with one or more substituents as described herein.

[0139] The term "hydroxyalkyl" means an alkyl group substituted with one or more hydroxy groups, wherein the alkyl group has the meaning as described herein; such examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxy-1-propyl, 3-hydroxy-1-propyl, 2,3-dihydroxypropyl and the like.

[0140] The term "cyanoalkyl" means an alkyl group substituted with one or more cyano groups, wherein the alkyl group has the meaning as described herein; such examples include, but are not limited to, cyanomethyl, 2-cyanoethyl, 2-cyano-1-propyl, 3-cyano-1-propyl, 2,3-dicyanopropyl and the like.

[0141] The term "aminoalkyl" means an alkyl group substituted by one or more amino groups, wherein the alkyl group has the meaning described herein; such examples include, but are not limited to, aminomethyl, 2-aminoethyl, 2-amino-1-propyl, 3-amino-1-propyl, 2,3-diaminopropyl and the like.

[0142] The term "haloalkyl" means that an alkyl group is substituted by one or more halogen atoms, wherein the alkyl group has the meaning as described herein, such examples include, but are not limited to, -CHF2, -CF3, -CHFCH2F, -CF2CHF2, -CH2CF3, -CHFCH3, -CH2CH2F, -CF2CH3, -CH2CF2CHF2, etc. In one embodiment, C1-C6 haloalkyl comprises fluorine-substituted C1-C6 alkyl; in another embodiment, C1-C4 haloalkyl comprises fluorine-substituted C1-C4 alkyl; in yet another embodiment, C1-C2 haloalkyl comprises fluorine-substituted C1-C2 alkyl.

[0143] The term "haloalkoxy" means that an alkoxy group is substituted by one or more halogen atoms, wherein the alkoxy group has the meaning as described in the present invention, such examples include, but are not limited to, -OCHF2, -OCF3, -OCHFCH2F, -OCF2CHF2, -OCH2CF3, -OCHFCH3, -OCH2CH2F, -OCF2CH3, -OCH2CF2CHF2, etc. In one embodiment, C1-C6 haloalkoxy comprises fluorine-substituted C1-C6 alkoxy; in another embodiment, C1-C4 haloalkoxy comprises fluorine-substituted C1-C4 alkoxy; in yet another embodiment, C1-C2 haloalkoxy comprises fluorine-substituted C1-C2 alkoxy.

[0144] The term "jk atoms" or "jk-membered" means that the cyclic group is composed of jk ring atoms, and the ring atoms include carbon atoms and / or heteroatoms such as O, N, S, and P; j and k are each independently any non-zero natural number, and k>j; "jk" includes j, k, and any natural number between the two. For example, "3-8 atoms" or "3-8-membered", "3-6 atoms" or "3-6-membered", "5-10 atoms" or "5-10-membered", "5-6 atoms" or "5-6-membered" means that the cyclic group is composed of 3-8 (i.e., 3, 4, 5, 6, 7, or 8), 3-6 (i.e., 3, 4, 5, or 6), 5-10 (i.e., 5, 6, 7, 8, 9, or 10), or 5-6 (i.e., 5 or 6) ring atoms, and the ring atoms include carbon atoms and / or heteroatoms such as O, N, S, and P. For another example, piperidinyl is a 6-atom heterocyclic group or a 6-membered heterocyclic group, and pyridinyl is a 6-atom heteroaryl group or a 6-membered heteroaryl group.

[0145] The term "jk pieces", "jk yuan" or "C j -C k " wherein j and k are independently any non-zero natural numbers, and k>j; for example, "1-4" means 1, 2, 3 or 4, "4-6 yuan" means 4 yuan, 5 yuan or 6 yuan; "C3-C6" means C3, C4, C5 or C6. And so on.

[0146] The terms "(alkoxy)-alkylene", "(alkylamino)-alkylene", "(cycloalkyl)-alkylene", "(heterocyclyl)-alkylene", "(aryl)-alkylene", "(heteroaryl)-alkylene" mean that the alkoxy, alkylamino, cycloalkyl, heterocyclyl, aryl or heteroaryl are each independently connected to the rest of the molecule through an alkylene, wherein the alkoxy, alkylamino, cycloalkyl, heterocyclyl, aryl, heteroaryl and alkylene have the meanings described in the present invention. For example, examples of (cycloalkyl)-alkylene include, but are not limited to, cyclopropylmethylene, cyclobutylmethylene, cyclopentylmethylene, cyclohexylmethylene, etc. For another example, examples of (aryl)-alkylene include, but are not limited to, phenylmethylene, phenylethylidene, phenylpropylene, etc. The (alkoxy)-alkylene, (alkylamino)-alkylene, (cycloalkyl)-alkylene, (heterocyclyl)-alkylene, (aryl)-alkylene, (heteroaryl)-alkylene are each independently optionally substituted with one or more substituents described herein.

[0147] The term "prodrug" refers to any compound that, when administered to a biological system, produces a drug, i.e., an active ingredient, due to spontaneous chemical reactions, enzyme-catalyzed chemical reactions, photolysis, and / or metabolic chemical reactions. A prodrug is thus a covalently modified analog or latent form of a therapeutically active compound.

[0148] "Heterocycle" or "heterocyclyl" include by way of example and are not limited to those described in: Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (WA Benjamin, New York, 1968), in particular Chapters 1, 3, 4, 6, 7 and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19 and 28 and J. Am. Chem. Soc. (1960) 82:5566. In a particular embodiment of the invention, "heterocycle" includes "carbocycle" as defined herein, in which one or more (e.g., 1, 2, 3 or 4) carbon atoms have been replaced by heteroatoms (e.g., O, N or S). The term "heterocycle" or "heterocyclyl" includes saturated rings, partially unsaturated rings and aromatic rings (i.e., heteroaromatic rings). Substituted heterocyclyl groups include, for example, heterocycles substituted with any of the substituents disclosed herein including carbonyl.

[0149] The terms "heterocyclyl" and "heterocycle" are used interchangeably herein and refer to a non-aromatic, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing 3 to 12 ring atoms, wherein the bicyclic or tricyclic ring system may include fused rings, bridged rings and spiro rings. One or more atoms in the ring are independently replaced by heteroatoms, and the heteroatoms have the meanings as described herein. In one embodiment, heterocyclyl is a monocyclic heterocyclyl consisting of 3-8 ring atoms (1-7 carbon atoms and 1-4 heteroatoms selected from N, O, P or S, where S or P is optionally substituted by one or more oxygen atoms to give groups like SO, SO2, PO, PO2); in another embodiment, heterocyclyl is a monocyclic heterocyclyl consisting of 3-6 ring atoms (1-5 carbon atoms and 1-4 heteroatoms selected from N, O, P or S, where S or P is optionally substituted by one or more oxygen atoms to give groups like SO, SO2, PO, PO2); in another embodiment, heterocyclyl is a bicyclic heterocyclyl consisting of 7-12 ring atoms (1-11 carbon atoms and 1-4 heteroatoms selected from N, O, P or S, where S or P is optionally substituted by one or more oxygen atoms to give groups like SO, SO2, PO, PO2). The heterocyclyl groups are optionally substituted by one or more substituents described herein.

[0150] The ring atoms of the heterocyclic group can be carbon groups or heteroatom groups. In which the -CH2- group of the ring is optionally replaced by -C(=O)-, the sulfur atom of the ring is optionally oxidized to S-oxide, and the nitrogen atom of the ring is optionally oxidized to N-oxygen compound. Examples of heterocyclic groups include, but are not limited to, oxirane, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, dithiolanyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepine Base, diazepine Base, thiazolin Examples of heterocyclic groups in which the -CH2- group is replaced by -C(=O)- include, but are not limited to, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, 2-piperidinyl, 3,5-dioxopiperidinyl, pyrimidinedione, and the like. Examples of heterocyclic groups in which the sulfur atom is oxidized include, but are not limited to, sulfolane, thiomorpholinyl 1,1-dioxide, and the like. The heterocyclic group is optionally substituted by one or more substituents described herein.

[0151] Examples of heterocycles include, by way of example and not limitation, pyridyl, dihydropyridyl, tetrahydropyridyl (piperidinyl), thiazolyl, tetrahydrothiophenyl, thiooxytetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthyl, indolyl, indolene, quinolyl, isoquinolyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidinonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolyl, tetrahydroisoquinolyl, decahydroquinolyl, octahydroisoquinolyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenolic flavinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl pyridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, isatoacyl, and bis-tetrahydrofuranyl.

[0152] The term "heteroaryl" refers to monocyclic, bicyclic and tricyclic ring systems containing 5-12 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms, wherein at least one ring system is aromatic, and at least one ring system contains one or more heteroatoms, wherein each ring system contains a ring consisting of 5-7 atoms. The heteroaryl group is usually, but not necessarily, connected to the parent molecule through the aromatic ring of the heteroaryl group. The term "heteroaryl" can be used interchangeably with the term "heteroaromatic ring", "aromatic heterocycle" or "heteroaromatic compound". The heteroaryl group is optionally substituted by one or more substituents described in the present invention. Non-limiting examples of suitable heteroatoms that can be included in the aromatic ring include oxygen, sulfur and nitrogen. Non-limiting examples of heteroaryl rings include all those aromatic rings listed in the definition of "heterocyclyl", including pyridyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothienyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazolyl, etc. In one embodiment, the heteroaryl group consisting of 5-10 ring atoms contains 1, 2, 3 or 4 heteroatoms independently selected from O, S or N.

[0153] Examples of heteroaryl groups include, but are not limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl , 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl, 1,3,5-triazinyl; also includes the following bicyclic rings, but is by no means limited to these bicyclic rings: benzimidazolyl, benzofuranyl, benzothiophenyl, indolyl (such as 2-indolyl), purinyl, quinolyl (such as 2-quinolyl, 3-quinolyl, 4-quinolyl), isoquinolyl (such as 1-isoquinolyl), [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, and the like.

[0154] The term "treat", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progression of, or preventing the condition or disorder, or one or more symptoms of such condition or disorder, to which the term applies. The term "treat", as used herein, refers to the act of treating, as "treating" is defined immediately above.

[0155] The compounds described herein also include reference to their physiologically acceptable salts, examples of which include salts derived from suitable bases, such as alkali metals or alkaline earth metals (e.g., Na + , Li + , K + , Ca +2 and Mg +2 ), ammonium and NR4 +(wherein R is as defined herein). Physiologically acceptable salts of nitrogen atoms or amino groups include: (a) acid addition salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and the like; (b) salts formed with organic acids, such as acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, isethionic acid, lactobionic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalene, and the like. (c) salts with elemental anions, such as chlorine, bromine and iodine. Physiologically acceptable salts of hydroxy compounds include salts of the anions of the compounds with hydroxy groups, such as sodium + and NR4 + A combination of appropriate cations.

[0156] Whenever a compound described herein is represented by more than one of the same designated group (e.g., "R" or "R 1 ”), it is to be understood that these groups may be the same or different, i.e., each group is independently selected.

[0157] Pharmaceutical preparations

[0158] The compounds of the present invention are formulated with conventional carriers and excipients, which will be selected in accordance with conventional practice. Although the active ingredients can be administered alone, it is preferred that they are formulated into pharmaceutical preparations. The preparations of the present invention, whether for veterinary or human use, contain at least one active ingredient as defined above and one or more acceptable carriers therefor, and optionally contain other therapeutic ingredients, especially those additional therapeutic ingredients as disclosed herein. The carrier must be "acceptable" in the sense that it is compatible with the other components of the formulation and is physiologically harmless to its recipient.

[0159] Preparations include those suitable for the above-mentioned routes of administration. Preparations can be conveniently prepared into unit dosage forms, and can be prepared by any method well-known in the pharmaceutical field. Technology and preparations can generally be found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA.). Such methods include the step of mixing the active ingredient with a carrier constituting one or more auxiliary components. In general, the preparation is prepared as follows: by uniformly and closely mixing the active ingredient with a liquid carrier or a finely dispersed solid carrier or both, and then, if necessary, the product is shaped.

[0160] Route of Administration:

[0161] One or more compounds of the present invention (referred to herein as active ingredients) are administered by any route suitable for the condition being treated. Suitable routes include oral, rectal, nasal, pulmonary, topical (including buccal and sublingual) and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), etc. It should be understood that the preferred route may vary, for example, depending on the condition of the recipient. DETAILED DESCRIPTION

[0162] In order to enable those skilled in the art to better understand the technical solution of the present invention, some non-limiting embodiments are further disclosed below to further illustrate the present invention in detail.

[0163] The reagents used in the present invention can be purchased from the market or prepared by the method described in the present invention.

[0164] In the present invention, nM means nanomole per liter; μM means micromole per liter; mmol means millimole; and equiv means equivalent.

[0165] The term “×g” indicates how many times the acceleration due to gravity is a centrifugal acceleration. For example, “5000×g” indicates 5000 times the acceleration due to gravity is a centrifugal acceleration.

[0166] body refers to a living mouse; lung refers to lungs; liver refers to liver; spleen refers to spleen; muscle refers to muscles.

[0167] DMG-PEG2000 stands for 1,2-dimyristoyl-sn-glyceryl methoxypolyethylene glycol 2000 (CAS: 160743-62-4); PEG-DMPE stands for dimyristoylphosphatidylethanolamine-polyethylene glycol; PEG-DPPC stands for dipalmitoylphosphatidylcholine polyethylene glycol; mPEG-STA stands for methoxypolyethylene glycol-monostearic acid; mPEG-PS stands for methoxypolyethylene glycol-phosphatidylserine; mPEG-DPPE stands for L-phosphatidyl Fatty acid ethanolamine PEG (purchased from https: / / www.aladdin-e.com / zh_cn / d163583.html); mPEG-DSPE represents methoxy-polyethylene glycol-phosphatidylethanolamine (CAS: 147867-65-0); DSPE-PEG5000 (mPEG-DSPE with a PEG molecular weight of 5000); mPEG-DMPE represents 2-myristyl stannoyl-3-phosphatidylethanolamine PEG (purchased from:

[0168] https: / / www.aladdin-e.com / zh_cn / d163570.html); mPEG2k-DMPE (mPEG-DMPE with a PEG molecular weight of 2000); ALC-0159 (methoxypolyethylene glycol ditetradecyl acetamide, CAS: 1849616-42-7); DOTAP stands for (2,3-dioleoyl-propyl)-trimethylamine sulfate; DOPE stands for 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DSPC stands for 1,2-distearoyl-sn-glycero-3-phosphocholine; Chol stands for cholesterol; DMPC stands for 1,2-dimyristoyl-sn-glycero-phosphocholine; PC stands for phosphatidylcholine; represents Tween 20; DPPC represents 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; =Span 80. EDCI means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. DMAP means 4-dimethylaminopyridine. HCTU means 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate. NMM means N-methylmorpholine. Ultra means dichloromethane / methanol / ammonia water = 75:22:3 (volume ratio). DCC means N,N'-dicyclohexylcarbodiimide.

[0169] L0461 represents the L0461 compound, L0462 represents the L0462 compound, L0463 represents the L0463 compound, and so on.

[0170] FLuc-mRNA indicates messenger RNA encoding firefly luciferase; EGFP-pDNA indicates plasmid encoding green fluorescent protein; EGFP-siRNA indicates small interfering RNA silencing the expression of enhanced green fluorescent protein gene; S-mRNA or Spike-mRNA indicates messenger RNA encoding S protein.

[0171] "IH" means subcutaneous injection; "IM" means intramuscular injection; "IV" means intravenous injection; "IP" means intraperitoneal injection.

[0172] FLuc-mRNA manufacturer: Shanghai Hongene Biotech Corporation.

[0173] The specific information of FLuc-mRNA stock solution is as follows:

[0174] Product name: FLuc-mRNA (N1-Me-pseudo U);

[0175] Product description: 1939 nucleotides in length;

[0176] Modifications: Fully substituted with N1-Me-pseudo UTP;

[0177] Concentration: 1.0 mg / mL;

[0178] Storage environment: 1mM sodium citrate, pH 6.4;

[0179] Storage requirements: -40℃ or below.

[0180] Example 1: Synthesis of hydrophobic chains of ionizable lipid compounds

[0181] The ionizable lipid compound of the present invention is produced by any previously known synthesis method known to a person of ordinary skill in the art. The raw materials in the preparation method, compound 1, compound 2, compound 4, compound 6, epoxy propionic acid, 1-decanol, 6AF6, SS10C, 2-hexyloctanoic acid, 2-hexyldecanoic acid, 1,4-butanediol, 1,6-hexanediol, 4AFV8, 6AFV6, 6AE6, oleylamine, 8MN, 10MN, 12MN, 14MN, Boc-2A, Boc-4A, Boc-6A, Boc-2DA, Boc anhydride, GABA, 8-pentadecanol, 1-decanol and other reagents can be purchased commercially or synthesized using conventional methods.

[0182] The simple synthesis method and specific process for synthesizing the hydrophobic chain of the ionizable lipid compound of the present invention are described as follows:

[0183] Synthesis of compound 3:

[0184]

[0185] HCTU (6.83 g) was added in portions to a solution of dodecylamine (2.78 g), epoxypropionic acid (1.32 g) and NMM (1.82 mL) in DMF (60 mL) and stirred for 12 h. The reaction system was diluted with 150 mL of ethyl acetate, and the resulting solution was washed with a saturated sodium chloride solution (50 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 5:1 (V / V)) to obtain a light yellow powdered compound 3 (3.1 g). 1H NMR (400MHz, Chloroform-d) δ6.15 (s, 1H), 3.40 (dd, J=4.8, 2.8Hz, 1H), 3.20 (dp, J=16.8, 6.4Hz, 2H), 2.95 (t, J=5.2Hz, 1H), 2.71 (dd, J=5.6, 2.8Hz, 1H), 1.45 (p, J=6.8Hz, 2H), 1.34–1.16 (m, 18H), 0.85 (t, J=6.8Hz, 3H); HRMS (ESI, m / z) [M+H] + Calculate for C 15 H 30 NO2:256.22711; found:256.22806.

[0186] Synthesis of compound 5:

[0187]

[0188] HCTU (9.10 g) was added to a solution of decylamine (3.46 g), epoxypropionic acid (1.76 g) and NMM (2.42 mL) in 60 mL DMF in portions and stirred for 12 h. The reaction system was diluted with 150 mL of ethyl acetate, and the resulting solution was washed with a saturated sodium chloride solution (50 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 5:1 (V / V)) to obtain a light yellow powdered compound 5 (3.2 g). 1 H NMR(400MHz,Chloroform-d)δ6.10(s,1H),3.43(dd,J=4.8,2.8Hz,1H),3.23(dp,J=19.6,6.4Hz,2H),2.98(t,J=5.2Hz, 1H), 2.73 (dd, J=5.6, 2.4Hz, 1H), 1.47 (p, J=6.8Hz, 2H), 1.33–1.19 (m, 14H), 0.87 (t, J=6.8Hz, 3H); HRMS (ESI, m / z) [M+H] + Calculate for C 13 H 26 NO2:228.19581; found:228.19937.

[0189] Synthesis of compound 7:

[0190]

[0191] Under ice bath conditions, DCC (4.47 g) was added to a mixed solution of dodecanol (4.10 g), epoxypropionic acid (1.76 g) and DMAP (244.4 mg) in 60 mL DCM. The resulting mixture was stirred for half an hour in an ice bath and then moved to room temperature and stirred for 12 h. The reaction solution was quenched with 100 mL of saturated ammonium chloride and extracted with dichloromethane (50 mL*3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 20: 1 (V / V)) to obtain a light yellow powder compound 7 (3.0 g). 1 H NMR (400MHz, Chloroform-d) δ4.16 (qt, J=10.8, 6.8Hz, 2H), 3.41 (dd, J=4.0, 2.4Hz, 1H), 2.93 (qd, J=6 .4,3.2Hz,2H),1.64(p,J=6.8Hz,2H),1.34–1.17(m,18H),0.86(t,J=6.8Hz,3H); HRMS(ESI,m / z)[M+H] + Calculate for C 15 H 29 O3:257.21112; found:257.21190.

[0192] Synthesis of compound GA-14C:

[0193]

[0194] Under ice bath conditions, DCC (1.36 g) was added to a mixed solution of tetradecanol (1.42 g), epoxypropionic acid (0.53 g) and DMAP (73.0 mg) in 60 mL DCM. The resulting mixture was stirred for half an hour in an ice bath and then moved to room temperature and stirred for 12 h. The reaction solution was quenched with 50 mL of saturated ammonium chloride and extracted with dichloromethane (50 mL*3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 20: 1 (V / V)) to obtain a white powdery compound GA-14C (0.96 g). 1 H NMR(400MHz,Chloroform-d)δ4.27–4.08(m,2H),3.43(dd,J=4.0,2.4Hz,1H),3.0 2–2.86(m,2H),1.66(p,J=6.8Hz,2H),1.38–1.20(m,22H),0.88(t,J=6.8Hz,3H).

[0195] Synthesis of compound GA-10C:

[0196]

[0197] Glycidyl alcohol (0.50 g) and 1-decanol (1.20 mL) were dissolved in 15 mL DCM. At 0 ° C, DMAP (71.0 mg) and DCC (1.29 g) were added and stirred at this temperature for 15 min, and then the reaction system was moved to room temperature and continued to stir for 12 h. The reaction was quenched with 5 mL saturated ammonium chloride solution, filtered through diatomaceous earth, washed with 60 mL DCM, and the filtrate was washed twice with 20 mL saturated ammonium chloride aqueous solution, and then washed twice with 20 mL saturated sodium chloride aqueous solution. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by column chromatography (PE: EA (i.e., petroleum ether: ethyl acetate) = 15: 1, v / v). GA-10C (0.699 g) was obtained as a colorless oily liquid. 1 H NMR(400MHz,Chloroform-d)δ4.22–4.08(m,2H),3.41(dd,J=4.0,2.8Hz,1H),2 .98–2.88(m,2H),1.70–1.60(m,2H),1.38–1.17(m,14H),0.86(t,J=6.8Hz,3H).

[0198] Synthesis of compound GA-6AF6:

[0199]

[0200] Glycidyl chloride (1.77 g) was mixed with 80 mL of DCM, and then 6AF6 (5.13 g) was added to the reaction system. DMAP (250.0 mg) and DCC (4.49 g) were added at 0°C, and the reaction was continued for 15 min, followed by reaction at room temperature for 12 h. The reaction was quenched with saturated ammonium chloride solution, filtered through diatomaceous earth, and the filtrate was washed twice with saturated ammonium chloride solution, then washed twice with sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography (PE: EA = 15: 1 (V / V)). GA-6AF6 (3.00 g) was obtained as a colorless oily liquid compound. 1 H NMR(400MHz,Chloroform-d)δ4.65(s,2H),4.28–4.10(m,2H),3.51(td,J=6.8,2.8Hz,4H),3.42(dd,J=4.0,2.8Hz,1H),3 .01–2.87(m,2H),1.71–1.65(m,2H),1.64–1.51(m,4H),1.44–1.24(m,10H),0.88(t,J=6.8Hz,3H); HRMS(ESI,m / z)[M+Na] +Calculate for C 16 H 30 NaO5:325.19855; found:325.19388.

[0201] Synthesis of compound GA-4E8B6:

[0202]

[0203] Mix 2-hexyloctanoic acid (10.53 g) and 1,4-butanediol (15.52 mL), and then add 290 mL of DCM. At 0°C, add DMAP (505.3 mg) and EDCI (12.58 g), react for 30 min, and then react at room temperature for 24 h. After the reaction is completed, dilute with DCM, wash twice with saturated ammonium chloride, then wash twice with saturated sodium chloride solution, dry with anhydrous sodium sulfate, and concentrate in vacuo. The crude product is purified by column chromatography (PE:EA=3:1 (V / V)) to obtain a light yellow oily liquid compound 4E8B6 (9.890 g). HRMS (ESI, m / z): [M+H] + calcd.For:C 18 H 36 O3,301.27372; found:301.27568.

[0204] Glycidyl ether (1.20 g) and 4E8B6 (4.10 g) were mixed, and then 48 mL of DCM was added. DMAP (165.0 mg) and EDCI (5.22 g) were added at 0°C and reacted for 30 min. The reaction was then carried out at room temperature for 12 h. The reaction solution was washed twice with a saturated ammonium chloride solution and twice with a saturated sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 7 / 1 (V / V)) to obtain a colorless oily liquid compound GA-4E8B6 (3.09 g). 1 HNMR(400MHz,Chloroform-d)δ4.21–4.07(m,2H),4.02(t,J=6.0Hz,2H),3.34(t,J=3.3Hz,1H),2.93–2.80(m,2H),2.30–2.18(m, 1H),1.75–1.59(m,4H),1.57–1.44(m,2H),1.41–1.30(m,2H),1.29–1.05(m,16H),0.79(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H]+ calcd.For:C 21 H 38 O5,371.27920; found:371.28013.

[0205] Synthesis of compound GA-6E8B6:

[0206]

[0207] 2-Hexyloctanoic acid (10.53 g) and 1,6-hexanediol (20.70 g) were mixed, and 300 mL of DCM was added. At 0°C, DMAP (505.3 mg) and EDCI (12.58 g) were added, and the mixture was reacted for 30 min, followed by stirring at room temperature for 12 h. After the reaction was completed, the mixture was diluted with DCM, washed twice with saturated ammonium chloride, then washed twice with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography (PE:EA=3:1 (V / V)) to obtain a light yellow oily liquid compound 6E8B6 (9.70 g).

[0208] Glycidyl ether (0.83 g) and 6E8B6 (3.41 g) were mixed, and then 25 mL of DCM was added to the reaction system. DMAP (114 mg) and EDCI (2.13 g) were added at 0°C, and the reaction was continued for 30 min, followed by 12 h at room temperature. The reaction was quenched with a saturated ammonium chloride solution, filtered through diatomaceous earth (7 μm), and the filtrate was washed twice with a saturated ammonium chloride solution, and then washed twice with a saturated sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 7 / 1 (V / V)) to obtain a light yellow oily liquid compound GA-6E8B6 (2.09 g). 1 H NMR(400MHz,Chloroform-d)δ4.19–4.06(m,2H),4.01(t,J=6.8Hz,2H),3.36(t,J=3.2Hz,1H),2.93–2.83(m,2H),2.31 –2.20(m,1H),1.69–1.45(m,6H),1.44–1.30(m,6H),1.30–1.04(m,16H),0.81(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H]+ calcd.For:C 23 H 42 O5,399.31050; found:399.31127.

[0209] Synthesis of compound GA-6E10B6:

[0210]

[0211] Mix 2-hexyldecanoic acid (10.01 g) and 1,6-hexanediol (18.42 g), and then add 250 mL of DCM. At 0°C, add DMAP (473.0 mg) and EDCI (11.21 g), react for 30 min, and then react at room temperature for 24 h. After the reaction, the reaction system was ice-bathed at 0°C for 15 min, then filtered with 7 μm diatomaceous earth, the filtrate was washed twice with saturated ammonium chloride, twice with saturated sodium chloride, dried with anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography (PE:EA=3 / 1 (V / V)) to obtain the product as a light yellow oily liquid compound 6E10B6 (9.05 g). HRMS (ESI, m / z): [M+H] + calcd.For:C 22 H 44 O3,357.33632; found:357.33778.

[0212] Glycidyl ether (0.83 g) and 6E10B6 (3.70 g) were mixed, and then 25 mL of DCM was added to the reaction system. DMAP (144.0 mg) and EDCI (2.13 g) were added at 0°C, and the reaction was continued for 30 min, followed by 12 h at room temperature. The reaction was quenched with a saturated ammonium chloride solution, filtered through diatomaceous earth (7 μm), and the filtrate was washed twice with a saturated ammonium chloride solution, and then washed twice with a saturated sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 7 / 1 (V / V)), and the final product was a light yellow oily liquid compound GA-6E10B6 (2.09 g). 1 H NMR(400MHz,Chloroform-d)δ4.23–4.09(m,2H),4.04(t,J=6.8Hz,2H),3.40(t,J=3.2Hz,1H),2.98–2.87(m,2H),2.34 –2.23(m,1H),1.71–1.49(m,6H),1.45–1.33(m,6H),1.32–1.14(m,20H),0.84(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H]+ calcd.For:C 25 H 46 O5,427.34180; found:427.34297.

[0213] Synthesis of compound GA-4AFV8:

[0214]

[0215] Glycidyl ether (1.21 g) was mixed with 30 mL of DCM, and then 4AFV8 (4.86 g) was added to the reaction system. At 0°C, DMAP (165.0 mg) and DCC (3.92 g) were added and mixed, and the resulting mixture was stirred in an ice bath for half an hour, then moved to room temperature and stirred for 12 h. The reaction was quenched with 5 mL of saturated NH4Cl aqueous solution, filtered, and washed with 10 mL of saturated NaCl aqueous solution. The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The crude product was purified by column chromatography (eluent: petroleum ether: ethyl acetate = 7:1 (V / V)) to obtain compound GA-4AFV8 (1.22 g) as a colorless oil. 1 H NMR(400MHz,Chloroform-d)δ5.50–5.39(m,1H),5.39–5.27(m,1H),4.64(s,2H), 4.22–4.10(m,2H),3.51(td,J=6.8,2.0Hz,4H),3.40(dd,J=4.0,2.8Hz,1H),2.98– 2.87(m,2H),2.31(q,J=7.2Hz,2H),2.04(p,J=7.6Hz,2H),1.71–1.62(m,2H),1.6 2–1.51(m,2H),1.43–1.33(m,4H),0.94(t,J=7.6Hz,3H).HRMS(ESI,m / z):[M+NH4] + calcd.For:C 16 H 28 O5,318.22750; found:318.22821.

[0216] Synthesis of compound GA-6AFV6:

[0217]

[0218] Glycidyl ether (1.95 g) was mixed with 37 mL of DCM, and then 6AFV6 (2.45 g,) was added to the system. DMAP (133.0 mg) and DCC (2.41 g) were added at 0°C and the mixture was stirred in an ice bath for half an hour, then moved to room temperature and stirred for 12 h. The reaction was quenched with 5 mL of saturated NH4Cl aqueous solution, filtered, and washed with 10 mL of saturated NaCl aqueous solution. The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The crude product was purified by column chromatography (eluent: petroleum ether: ethyl acetate = 7:1 (V / V)) to obtain a colorless oily compound GA-6AFV6 (0.97 g). 1H NMR(400MHz,Chloroform-d)δ5.51–5.41(m,1H),5.41–5.30(m,1H),4.65(s,2H), 4.28–4.13(m,2H),3.53(dt,J=12.0,6.8Hz,4H),3.41(dd,J=4.0,2.8Hz,1H),2.9 9–2.87(m,2H),2.32(q,J=7.2Hz,2H),2.03(q,J=6.8Hz,2H),1.81–1.70(m,2H),1 .70–1.59(m,2H),1.37–1.25(m,4H),0.88(t,J=6.8Hz,3H).HRMS(ESI,m / z):[M+H] + calcd.For:C 16 H 28 O5,301.20095; found:301.20201.

[0219] Synthesis of compound GA-6AE6:

[0220]

[0221] Glycidyl ether (1.63 g) and 6AE6 (4.58 g) were mixed, and then 65 mL of DCM was added to the reaction system. DMAP (224.0 mg) and EDCI (5.35 g) were added at 0°C, and the resulting mixture was stirred in an ice bath for 30 min, then moved to room temperature and stirred for 12 h. The reaction solution was diluted with 150 mL of DCM and washed with saturated aqueous NaCl solution (80 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The crude product was purified by column chromatography (eluent: petroleum ether: ethyl acetate = 6:1 (V / V)) to obtain a colorless oil compound GA-6AE6 (3.20 g). HRMS (ESI, m / z): [M+Na]+ calcd.For: C 17 H 32 O5,339.21420; found:339.21558.

[0222] Synthesis of compound GA-18OleN:

[0223]

[0224] Glycidyl ether (1.30 g) and oleylamine (4.73 g) were mixed, and 50 mL of DMF was added. NMM (1.83 mL) and HCTU (6.72 g) were then added to the reaction system, and the reaction was allowed to react at room temperature for 12 h. The reaction solution was concentrated under reduced pressure in vacuo, then diluted with EA, and washed with saturated sodium chloride three times (if floccules were precipitated and dissolved in the organic phase, 7 μm diatomaceous earth was required). The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography (dry loading, petroleum ether: ethyl acetate = 2 / 1 (V / V)) to obtain a light yellow solid compound GA-18OleN (2.093 g). 1 H NMR(400MHz,Chloroform-d)δ6.12(s,1H),5.48–5.20(m,2H),3.45–3.38(m,1H),3.31–3.11(m,2H),2.96(t,J=5.2H z,1H),2.72(dd,J=6.0,2.8Hz,1H),2.15–1.78(m,4H),1.56–1.38(m,2H),1.38–1.17(m,22H),0.86(t,J=6.8Hz,3H).

[0225] Synthesis of compound GA-8MN:

[0226]

[0227] Add EDCI (4.89 g) and DMAP (0.19 g) to a mixed solution of epoxypropionic acid (2.15 g) and 100 mL DMF under ice bath, and continue stirring for 30 min. Add 8MN (2.15 g) to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the target product GA-8MN (2.19 g). GA-8MN: HRMS (ESI, m / z): [M+H] +

[0228] calcd.For C 12 H 24 NO2,214.18015; found:214.18013.

[0229] Synthesis of compound GA-10MN:

[0230]

[0231] Add EDCI (3.50 g) and DMAP (0.10 g) to a mixed solution of epoxypropionic acid (1.46 g) and 80 mL DMF under ice bath, and continue stirring for 30 min. Add 10MN (1.42 g) to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the target product GA-10MN (1.04 g). GA-10MN: HRMS (ESI, m / z): [M+H] + calcd.For C 14 H 28 NO2,242.21145; found:242.21238.

[0232] Synthesis of compound GA-12MN:

[0233]

[0234] Add EDCI (4.14 g,) and DMAP (0.22 g) to a mixed solution of epoxypropionic acid (1.90 g) and 100 mL DMF under ice bath, and continue stirring for 30 min. Add 12MN (3.59 g) to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the target product GA-12MN (3.84 g). GA-12MN: HRMS (ESI, m / z): [M+H] + calcd.For C 16 H 32 NO2,270.24275; found:270.24537.

[0235] Synthesis of compound GA-14MN:

[0236]

[0237] Add EDCI (4.22 g) and DMAP (0.19 g) to a mixed solution of epoxypropionic acid (1.76 g) and 120 mL DMF under ice bath, and continue stirring for 30 min. Add 14MN (2.27 g) to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the target product GA-14MN (1.79 g). GA-14MN: HRMS (ESI, m / z): [M+H] + calcd.For C 18 H 36 NO2,298.27405; found:298.27392.

[0238] Synthesis of compound GA-2A8B6:

[0239]

[0240] Under ice bath, EDCI (3.62 g) and DMAP (0.15 g) were added to a mixed solution of 2-hexyloctanoic acid 8B6 (3.58 g) and 100 mL DCM, and stirring was continued for 30 minutes under ice bath; N-(tert-butyloxycarbonyl)ethanolamine Boc-2A (2.10 g) was added to the above system, and the reaction was carried out at room temperature for 12 h. The reaction system was diluted with DCM, washed with saturated brine, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by rapid medium pressure preparative chromatography using petroleum ether: ethyl acetate = 4:1 (v / v) as eluent to obtain compound Boc-2A8B6 (4.37 g).

[0241] The Boc-2A8B6 obtained in the above step was dissolved in TFA / DCM (27 mL, 1:2, v / v) and reacted at room temperature for 2 h. After TLC monitoring showed that the reaction was completed, the TFA (trifluoroacetic acid) and DCM were removed by concentration under reduced pressure, the residue was diluted with 200 mL DCM, washed twice with 100 mL saturated sodium bicarbonate solution, the organic phase was collected, and dried over anhydrous sodium sulfate; DCM was removed by concentration under reduced pressure, and the residue was purified by rapid medium pressure preparative chromatography using DCM / Ultra=2:1 (v / v) as eluent to obtain compound 2A8B6 (2.65 g,).

[0242] Add EDCI (4.20 g) and DMAP (0.12 g) to a mixed solution of epoxypropionic acid (1.73 g) and 100 mL DMF under ice bath, and continue stirring for 30 min. Add 2A8B6 (2.66 g) obtained in the previous step to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the target product GA-2A8B6 (0.75 g). 1 H NMR(400MHz,Chloroform-d)δ6.38(s,1H),4.23–4.05(m,2H),3.59–3.47(m,2H),3.44(dd,J=4.8,2.4Hz,1H),3.02–2.94(m,1H),2.74(dd, J=5.6,2.4Hz,1H),2.41–2.25(m,1H),1.63–1.52(m,2H),1.49–1.37(m,2H),1.31–1.18(m,16H),0.94–0.80(m,6H).HRMS(ESI,m / z):[M+H] + calcd.For C 19 H 36 NO4,342.26388; found:342.26362.

[0243] Synthesis of compound GA-4A8B6:

[0244]

[0245] Under ice bath, add EDCI (1.55g,) and DMAP (65.0mg) to the mixed solution of 2-hexyloctanoic acid 8B6 (1.53g) and 50mL DCM, and continue stirring under ice bath for 30 minutes; add 4-(N-tert-butyloxycarbonylamino)-1-butanol Boc-4A (1.03g) to the above system, and react at room temperature for 12h. The reaction system is diluted with DCM, washed with saturated brine, and the organic phase is dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue is purified by rapid medium pressure preparative chromatography using petroleum ether: ethyl acetate = 4:1 (v / v) as eluent to obtain compound Boc-4A8B6 (1.75g,).

[0246] The Boc-4A8B6 obtained in the above step was dissolved in TFA / DCM (10.5 mL, 1:2, v / v) and reacted at room temperature for 2 h. After TLC monitoring showed that the reaction was completed, the TFA and DCM were removed by concentration under reduced pressure, the residue was diluted with 200 mL DCM, washed twice with 100 mL saturated sodium bicarbonate solution, the organic phase was collected, and dried over anhydrous sodium sulfate; DCM was removed by concentration under reduced pressure, and the residue was purified by rapid medium pressure preparative chromatography using DCM / Ultra=2:1 (v / v) as eluent to obtain compound 4A8B6 (1.10 g).

[0247] Under ice bath, add EDCI (1.59 g) and DMAP (46.0 mg) to a mixed solution of epoxypropionic acid (0.65 g) and 50 mL DMF, and continue stirring for 30 min. Add 4A8B6 (1.11 g) obtained in the previous step to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the target product GA-4A8B6 (0.83 g). 1 H NMR(400MHz,Chloroform-d)δ6.16(s,1H),4.07(t,J=6.4Hz,2H),3.44(dd,J=4.8,2.8Hz,1H),3.37–3.18(m,2H),2.99(t,J=5.2Hz,1H),2.74(d d,J=5.6,2.8Hz,1H),2.37–2.24(m,1H),1.63–1.51(m,6H),1.47–1.37( m,2H),1.32–1.20(m,16H),0.87(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H] + calcd.For C 21 H 40 NO4,370.29518; found:370.29600.

[0248] Synthesis of compound GA-6A8B6:

[0249]

[0250] Under ice bath, EDCI (1.34 g) and DMAP (56 mg) were added to a mixed solution of 2-hexyloctanoic acid 8B6 (1.33 g) and 100 mL DCM, and the mixture was stirred for 30 minutes under ice bath; 4-(N-tert-butyloxycarbonylamino)-1-hexanol (Boc-6A) (2.69 g) was added to the above system, and the reaction was carried out at room temperature for 12 h. The reaction system was diluted with DCM, washed with saturated brine, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by rapid medium pressure preparative chromatography using petroleum ether: ethyl acetate = 4:1 (v / v) as eluent to obtain compound Boc-6A8B6 (1.45 g).

[0251] The Boc-6A8B6 obtained in the above step was dissolved in a TFA / DCM mixed solvent (27 mL, 1:2, v / v) and reacted at room temperature for 2 h. After TLC monitoring showed that the reaction was completed, the TFA and DCM were removed by concentration under reduced pressure, the residue was diluted with 200 mL DCM, washed twice with 100 mL saturated sodium bicarbonate solution, the organic phase was collected, and dried over anhydrous sodium sulfate; DCM was removed by concentration under reduced pressure, and the residue was purified by rapid medium pressure preparative chromatography using DCM / Ultra=2:1 (v / v) as the eluent to obtain compound 6A8B6 (0.90 g).

[0252] Add EDCI (1.16 g) and DMAP (33.0 mg) to a mixed solution of epoxypropionic acid (0.48 g) and 100 mL DMF under ice bath, and continue stirring for 30 min. Add 6A8B6 (0.88 g) obtained in the previous step to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the target product GA-6A8B6 (0.74 g). 1 H NMR(400MHz,Chloroform-d)δ6.12(s,1H),4.05(t,J=6.8Hz,2H),3.43(dd,J=4.8,2.8Hz,1H),3.33–3.14(m,2H),2.98(t,J=5.2Hz,1H) ,2.73(dd,J=5.6,2.8Hz,1H),2.36–2.23(m,1H),1.64–1.32(m,12H),1.29–1.20(m,16H),0.86(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H] + calcd.For C 23 H 44 NO4,398.32648; found:398.32640.

[0253] Synthesis of compound GA-2A10B6:

[0254]

[0255] Under ice bath, EDCI (3.62 g) and DMAP (0.15 g) were added to a mixed solution of 2-hexyldecanoic acid 10B6 (3.82 g) and 100 mL DCM, and the mixture was stirred for 30 minutes under ice bath; 2-(N-tert-butyloxycarbonylamino)-1-ethanol Boc-2A (2.10 g) was added to the above system, and the reaction was carried out at room temperature for 12 h. The reaction system was diluted with DCM, washed with saturated brine, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by rapid medium pressure preparative chromatography using petroleum ether: ethyl acetate = 4:1 (v / v) as eluent to obtain compound Boc-2A10B6 (4.86 g).

[0256] The Boc-2A10B6 obtained in the above step was dissolved in TFA / DCM (28.5 mL, 1:2, v / v) and reacted at room temperature for 2 h. After TLC monitoring showed that the reaction was completed, the TFA and DCM were removed by concentration under reduced pressure, the residue was diluted with 200 mL DCM, washed twice with 100 mL saturated sodium bicarbonate solution, the organic phase was collected, and dried over anhydrous sodium sulfate; DCM was removed by concentration under reduced pressure, and the residue was purified by rapid medium pressure preparative chromatography using DCM / Ultra=2:1 (v / v) as eluent to obtain compound 2A10B6 (2.74 g).

[0257] Add EDCI (3.92 g) and DMAP (0.11 g) to a mixed solution of epoxypropionic acid (1.73 g) and 100 mL DMF under ice bath, and continue stirring for 30 min. Add 2A10B6 (2.73 g) obtained in the previous step to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the product GA-2A10B6 (2.34 g). 1H NMR(400MHz,Chloroform-d)δ6.38(s,1H),4.24–4.05(m,2H),3.62–3.47(m,2H),3.44(dd,J=4.8,2.8Hz,1H),2.98(t,J=5.2Hz,1H),2.74(dd, J=5.6,2.8Hz,1H),2.43–2.23(m,1H),1.62–1.52(m,2H),1.49–1.37(m,2H),1.33–1.19(m,20H),0.87(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H] + calcd.For C 21 H 40 NO4,370.29518; found:370.29420.

[0258] Synthesis of compound GA-4A10B6:

[0259]

[0260] Under ice bath, EDCI (1.53 g) and DMAP (0.06 g) were added to a mixed solution of 2-hexyldecanoic acid (10B6) (1.63 g) and 50 mL DCM, and the mixture was stirred for 30 minutes under ice bath; 4-(N-tert-butyloxycarbonylamino)-1-butanol Boc-4A (1.01 g) was added to the above system, and the reaction was carried out at room temperature for 12 hours. The reaction system was diluted with DCM, washed with saturated brine, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by rapid medium pressure preparative chromatography using petroleum ether: ethyl acetate = 4:1 (v / v) as eluent to obtain compound Boc-4A10B6 (2.05 g).

[0261] The Boc-4A10B6 obtained in the above step was dissolved in TFA / DCM (18.0 mL, 1:2, v / v) and reacted at room temperature for 2 h. After TLC monitoring showed that the reaction was completed, the TFA and DCM were removed by concentration under reduced pressure, the residue was diluted with 200 mL DCM, washed twice with 100 mL saturated sodium bicarbonate solution, the organic phase was collected, and dried over anhydrous sodium sulfate; DCM was removed by concentration under reduced pressure, and the residue was purified by rapid medium pressure preparative chromatography using DCM / Ultra=2:1 (v / v) as eluent to obtain compound 4A10B6 (1.97 g).

[0262] Add EDCI (2.58 g) and DMAP (0.07 g) to a mixed solution of epoxypropionic acid (1.06 g) and 100 mL DMF under ice bath, and continue stirring for 30 min. Add 4A10B6 (1.97 g) obtained in the previous step to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the product GA-4A10B6 (1.87 g). 1 H NMR(400MHz,Chloroform-d)δ6.16(s,1H),4.06(t,J=6.4Hz,2H),3.53–3.39(m,1H),3.38–3.18(m,2H),2.98(t,J=5.2Hz,1H),2.73(dd,J= 5.6,2.8Hz,1H),2.35–2.24(m,1H),1.68–1.50(m,6H),1.48–1.36(m,2H),1.33–1.17(m,20H),0.86(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H] + calcd.For C 23 H 44 NO4,398.32648; found:398.32794.

[0263] Synthesis of compound GA-6A10B6:

[0264]

[0265] Under ice bath, EDCI (1.32 g) and DMAP (0.06 g) were added to a mixed solution of 2-hexyldecanoic acid 10B6 (1.41 g) and 50 mL DCM, and the mixture was stirred for 30 minutes under ice bath; 6-(N-tert-butyloxycarbonylamino)-1-hexanol Boc-6A (1.0 g) was added to the above system, and the reaction was carried out at room temperature for 12 h. The reaction system was diluted with DCM, washed with saturated brine, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by rapid medium pressure preparative chromatography using petroleum ether: ethyl acetate = 4:1 (v / v) as eluent to obtain compound Boc-6A10B6 (2.04 g).

[0266] The Boc-6A10B6 obtained in the above step was dissolved in TFA / DCM (10.5 mL, 1:2, v / v) and reacted at room temperature for 2 h. After TLC monitoring showed that the reaction was completed, the TFA and DCM were removed by concentration under reduced pressure, the residue was diluted with 200 mL DCM, washed twice with 100 mL saturated sodium bicarbonate solution, the organic phase was collected, and dried over anhydrous sodium sulfate; DCM was removed by concentration under reduced pressure, and the residue was purified by rapid medium pressure preparative chromatography using DCM / Ultra=2:1 (v / v) as eluent to obtain compound 6A10B6 (1.07 g).

[0267] Add EDCI (1.29 g) and DMAP (0.04 g) to a mixed solution of epoxypropionic acid (0.53 g) and 100 mL DMF under ice bath, and continue stirring for 30 min. Add 6A10B6 (1.07 g) obtained in the previous step to the above system, and move the reaction system to room temperature and stir for 12 h. Remove DMF under reduced pressure, dissolve the residue with 300 mL ethyl acetate, wash the resulting solution twice with 100 mL saturated brine, dry the organic phase over anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain the product GA-6A10B6 (0.70 g). 1 H NMR(400MHz,Chloroform-d)δ6.11(s,1H),4.05(t,J=6.8Hz,2H),3.43(dd,J=4.8,2.6Hz,1H),3.35–3.13(m,2H),2.98(t,J= 5.2Hz,1H),2.73(dd,J=5.6,2.8Hz,1H),2.36–2.23(m,1H),1.65–1.20(m,32H),0.87(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H] + calcd.For C 25 H 48 NO4,426.35778; found:426.35713.

[0268] Synthesis of compound GA-2DA8B6:

[0269]

[0270] Under ice bath, EDCI (1.82g) and DMAP (77.0mg) were added to a mixed solution of alcohol Boc-2DA (1.01g), 2-hexyloctanoic acid 8B6 (1.79g) and 30mL DCM. The resulting mixture was stirred for 30 minutes under ice bath, then heated to room temperature and stirred for 12h. The reaction solution was diluted with 100mL DCM and washed with saturated NaCl aqueous solution (50mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 4:1 (V / V)) to obtain a colorless oil Boc-2DA8B6 (1.90g).

[0271] The Boc-2DA8B6 obtained in the above-mentioned synthesis step was dissolved in a mixture of TFA and DCM (18.0 mL, 1: 2, v / v), and stirred at room temperature for 2 hours. TFA and DCM were removed under reduced pressure, the residue was dissolved in 100 mL DCM, and washed three times with 50 mL saturated NaHCO3 aqueous solution. The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: DCM: Ultra = 2: 1 (V / V)) to obtain colorless oily 2DA8B6 (1.25 g).

[0272] Under ice bath conditions, EDCI (1.98 g) and DMAP (57.0 mg) were added to a mixed solution of alcohol 2DA8B6 (1.07 g), epoxypropionic acid (0.81 g) and 30 mL of DMF. The resulting mixture was stirred for 30 minutes under ice bath conditions, then heated to room temperature and stirred for 12 h. The reaction solution was diluted with 100 mL of ethyl acetate and washed with saturated NaCl aqueous solution (50 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 2: 1) to obtain compound GA-2DA8B6 (1.30 g) as a colorless oil. 1 H NMR(400MHz,Chloroform-d)δ6.70(s,1H),5.99(t,J=5.2Hz,1H),3.55–3.27(m,5H),2.99–2.95(m,1H),2.77(dd,J=5.6,2.5Hz, 1H),2.04–1.95(m,1H),1.62–1.50(m,2H),1.44–1.35(m,2H),1.32–1.18(m,16H),0.86(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H] + calcd.ForC 19 H 37N2O3,341.27987; found:341.27937.

[0273] Synthesis of compound GA-GABA8B7:

[0274]

[0275] Gamma-aminobutyric acid GABA (1.04 g) was dissolved in 2 mL of water and diluted with 50 mL of methanol. After cooling with an ice-water bath for 5 minutes, Boc anhydride (2.34 g) was added, and the resulting mixture was moved to room temperature and stirred for 30 minutes, then the solvent was removed under reduced pressure. The residue was purified by silica gel chromatography to obtain Boc-GABA (1.82 g) as a white solid.

[0276] Under ice bath, EDCI (1.70g) and DMAP (77.0mg) were added to a mixed solution of Boc-GABA (1.42g), 8-pentadecanol (1.40g) and 50mL DCM. The resulting mixture was stirred for 30 minutes under ice bath, then heated to room temperature and stirred for 12h. The reaction solution was diluted with 100mL DCM and washed with saturated NaCl aqueous solution (50mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 4:1 (V / V)) to obtain a colorless oil Boc-GABA8B7 (1.82g).

[0277] The Boc-GABA8B7 obtained in the above synthesis step was dissolved in a mixture of TFA and DCM (10.5 mL, 1: 2, v / v) and stirred at room temperature for 2 hours. TFA and DCM were removed under reduced pressure, the residue was dissolved in 100 mL DCM, and washed three times with 50 mL saturated NaHCO3 aqueous solution. The organic phase was dried over anhydrous sodium sulfate, filtered, the solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: DCM: Ultra = 2: 1 (V / V)) to obtain GABA8B7 (1.08 g) as a colorless oil.

[0278] Under ice bath conditions, EDCI (1.21 g) and DMAP (35.0 mg) were added to a mixed solution of alcohol GABA8B7 (1.07 g), epoxypropionic acid (0.49 g) and 20 mL of DMF. The resulting mixture was continued to be stirred for 30 minutes under ice bath conditions, then heated to room temperature and stirred for 12 h. The reaction solution was diluted with 150 mL of ethyl acetate and washed with saturated NaCl aqueous solution (50 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 2: 1) to obtain a colorless oily compound GA-GABA8B7 (0.73 g). 1 H NMR (400MHz, Chloroform-d) δ6.29(s,1H),4.86(p,J=6.4Hz,1H),3.42(dd,J=4.8,2.8Hz,1H),3.28(th,J=13.6,6.8Hz,2H),2.97(t,J=5.2Hz,1H),2.74(d d,J=6.0,2.8Hz,1H),2.31(t,J=7.2Hz,2H),1.82(p,J=7.2Hz,2H),1.50(q,J= 6.4Hz,4H),1.36–1.18(m,20H),0.87(t,J=6.8Hz,6H).HRMS(ESI,m / z):[M+H] + calcd.For C 22 H 42 NO4,384.31083; found:384.30914.

[0279] Synthesis of compound GA-GABA10C:

[0280]

[0281] Gamma-aminobutyric acid GABA (1.04 g) was dissolved in 2 mL of water and diluted with 50 mL of methanol. After cooling with an ice-water bath for 5 minutes, Boc anhydride (2.34 g) was added, and the resulting mixture was moved to room temperature and stirred for 30 minutes, then the solvent was removed under reduced pressure. The residue was purified by silica gel chromatography to obtain Boc-GABA (1.82 g) as a white solid.

[0282] Under ice bath, EDCI (4.06g) and DMAP (242.0mg) were added to a mixed solution of alcohol Boc-GABA (3.98g), 1-decanol (3.80g) and 100mL DCM. The resulting mixture was stirred for 30 minutes under ice bath, then heated to room temperature and stirred for 12h. The reaction solution was diluted with 200mL DCM and washed with saturated NaCl aqueous solution (50mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 4:1 (V / V)) to obtain Boc-GABA10C (5.13g) as a colorless oil.

[0283] The Boc-GABA10C obtained in the above synthesis step was dissolved in a mixture of TFA and DCM (10.5 mL, 1: 2, v / v) and stirred at room temperature for 2 hours. TFA and DCM were removed under reduced pressure, the residue was dissolved in 100 mL DCM, and washed three times with 50 mL saturated NaHCO3 aqueous solution. The organic phase was dried over anhydrous sodium sulfate, filtered, the solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: DCM: Ultra = 2: 1 (V / V)) to obtain GABA10C HCl (2.30 g, quantitative) as a colorless oil.

[0284] Under ice bath conditions, EDCI (2.82 g) and DMAP (148.0 mg) were added to a mixed solution of epoxypropionic acid (1.06 g) and 40 mL of DMF. The resulting mixture was stirred at 0°C for 30 minutes, and GABA10C (2.24 g) and TEA (1.12 mL) were added, and the resulting reaction mixture was heated to room temperature and stirred for 12 h. The reaction solution was diluted with 200 mL of ethyl acetate and washed with saturated NaCl aqueous solution (50 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 1: 1 (V / V)) to obtain a colorless oily compound GABA10C (0.82 g). 1H NMR(400MHz,Chloroform-d)δ6.28(s,1H),4.06(t,J=6.8Hz,2H),3.43(dd,J=4.8,2.8Hz,1H),3.38–3.21(m,2H),2.98(dd,J=5.6,4.8Hz,1H),2.75(dd ,J=5.6,2.8Hz,1H),2.33(t,J=7.6Hz,2H),1.83(p,J=7.2Hz,2H),1.66–1.5 6(m,3H),1.37–1.21(m,14H),0.88(t,J=6.8Hz,3H).HRMS(ESI,m / z):[M+H] + calcd.For C 17 H 32 NO4,314.23258; found:314.23084.

[0285] Example 2: Preparation of lipid compounds

[0286] Preparation of compound L0463:

[0287]

[0288] 0.1 mmol of amine E and 0.78 mmol of compound 3 were dissolved in 2.0 mL of isopropanol, and the resulting solution was stirred at 80° C. for 24 h. The isopropanol was removed by concentration under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the target product compound L0463.

[0289] Preparation of compound L0474:

[0290]

[0291] 0.1 mmol of amine F and 0.78 mmol of compound 3 were dissolved in 2.0 mL of isopropanol, and the resulting solution was stirred at 80° C. for 24 h. The isopropanol was removed by concentration under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the target product compound L0474.

[0292] Appropriate amounts of the obtained compounds L0463 and L0474 were taken respectively, and their hydrogen spectra and mass spectra were detected. The results are as follows:

[0293] Compound L0463 hydrogen spectrum: 1H NMR(400MHz,Chloroform-d)δ7.13(t,J=6.0Hz,6H),4.14(dd,J=8.0,3.2Hz,6H),3.33–3.09(m, 12H),3.05–2.55(m,24H),1.49(p,J=6.8Hz,12H),1.41–1.11(m,108H),0.86(t,J=6.8Hz,18H).

[0294] Mass spectrum of compound L0463: HRMS (ESI, m / z): [M+H] + calcd.For C 96 H 193 N 10 O 12 ,1679.48275; found1679.48310.

[0295] Compound L0474 hydrogen spectrum: 1 H NMR(400MHz,Chloroform-d)δ7.08(t,J=6.0Hz,6H),4.08(dd,J=8.8,3.6Hz,6H),3.20(q,J=6.8Hz,12H),2.90(dd,J=13 .6,4.0Hz,6H),2.76–2.57(m,12H),2.39–2.23(m,6H),1.61–1.41(m,18H),1.33–1.20(m,108H),0.86(t,J=6.8Hz,18H).

[0296] Mass spectrum of compound L0474: HRMS (ESI, m / z): [M+H] + calcd.For C 99 H 199 N 10 O 12 ,1721.52970; found:1721.53481.

[0297] Example 3: Compound L0461, compound L0462, compound L0464, compound L0465, compound L0467, compound L0468, compound L0469, compound L0470, compound L0471, compound L0472, compound L0473, compound L0475, compound L0476, compound L0477, compound L0478, compound L0479, compound L0480, compound L0481, compound L0482, compound L0483, compound L0484, compound L 0485, compound L0486, compound L0487, compound L0488, compound L0489, compound L0490, compound L0491, compound L0492, compound L0493, compound L0494, compound L0495, compound L0496, compound L0497, compound L0498, compound L0499, compound L0500, compound L0501, compound L0502, compound L0503, compound L0504, compound L0505 and method for preparing compound L0506

[0298] The compound L0461, compound L0462, compound L0464, compound L0465, compound L0467, compound L0468, compound L0469, compound L0470, compound L0471, compound L0472, compound L0473, compound L0475, compound L0476, compound L0477, compound L0478, compound L0479, compound L0480, compound L0481, compound L0482, compound L0483, compound L0484, compound L0485, compound L0486, compound L0487, compound L0488, compound L0489, compound L0490, compound L0491, compound L0492, compound L0493, compound L0494, compound L0495 Compounds L0495, L0496, L0497, L0498, L0499, L0500, L0501, L0502, L0503, L0504, L0505 and L0506 were obtained by epoxy ring-opening reaction of commercially available amines and glycidyl / amides. According to the structural characteristics of the target product, 0.1 mmol of amine E or amine F and 0.78 mmol of glycidyl / amide compound (the glycidyl / amide compound has a hydrophobic chain structure synthesized as shown in Example 1 or a hydrophobic chain structure prepared by a similar preparation method as Example 1, and the corresponding glycidyl / amide compound is selected according to the structural characteristics of the target product) substrate were dissolved in 2.0 mL of isopropanol, and the obtained solution was stirred at 80° C. for 24 h. The isopropanol was removed by concentration under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the target products L0461-L0506, respectively.

[0299] Appropriate amounts of the obtained compounds L0461-L0506 were taken respectively, and their hydrogen spectra and mass spectra were detected. The results are as follows:

[0300] Compound L0461: 1 H NMR(400MHz,Chloroform-d)δ4.27(dd,J=8.0,3.2Hz,6H),4.23–4.01(m,12H),3.25–2.52(m,24 H),1.64(p,J=7.2Hz,12H),1.39–1.20(m,108H),0.87(t,J=6.8Hz,18H).HRMS(ESI,m / z):[M+H] + calcd.For C 96 H 187 N4O 18 ,1685.38685; found1685.38831.

[0301] Compound L0462: 1 H NMR(400MHz,Chloroform-d)δ7.14(t,J = 6.0Hz,6H),4.12(dd,J = 8.0,3.2Hz,6H),3.30–3.10(m,12H),3.03–2.80(m,10H),2.78–2.53(m,14H),1.58–1.40(m,12H),1.36–1.13(m,84H),0.86(t,J = 6.8Hz,18H).HRMS(ESI,m / z):[M+H]+ calcd.ForC 84 H 169 N 10 O 12 ,1510.29160;found 1510.29342.

[0302] Compound L0464: 1 H NMR(400MHz,Chloroform-d)δ4.64(s,12H),4.27(dd,J = 8.0,3.2Hz,6H),4.21–4.05(m,12H),3.50(t,J = 6.8Hz,24H),3.14–2.61(m,24H),1.76–1.47(m,36H),1.44–1.27(m,60H),0.88(t,J = 6.8Hz,18H).HRMS(ESI,m / z):[M+H] + calcd.ForC 102 H 199 N4O 30 ,1961.41972;found 1961.41685.

[0303] Compound L0465: 1 H NMR(400MHz,Chloroform-d)δ5.53–5.42(m,6H),5.39–5.31(m,6H),4.65(s,12H),4.27(dd,J = 8.0,3.2Hz,6H),4.21–4.08(m,12H),3.52(td,J = 6.8,3.6Hz,24H),3.09–2.63(m,24H),2.32(q,J = 7.2Hz,12H),2.05(p,J = 7.6Hz,12H),1.69–1.62(m,12H),1.61–1.54(m,12H),1.41–1.34(m,24H),0.96(t,J = 7.6Hz,18H).HRMS(ESI,m / z):[M+H] +calcd.For C 102 H 187 N4O 30 ,1949.32582;found 1949.31849.

[0304] Compound L0467: 1 H NMR(400MHz,Chloroform-d)δ5.59–5.39(m,6H),5.39–5.23(m,6H),4.65(s,12H),4.26(dd,J=8.0,3.2Hz,6H),4.21–4.03(m,12H),3.51(td,J=6.8,3.2Hz,24H),3.38–3.06(m,6H),2.94–2.60(m,18H),2.32(q,J=7.0Hz,12H),2.11–1.85(m,18H),1.71–1.52(m,24H),1.43–1.32(m,24H),0.95(t,J=7.6Hz,18H).HRMS(ESI,m / z):[M+H] + calcd.For C 105 H 193 N4O 30 ,1991.37277;found 1991.37367.

[0305] Compound L0468: 1 H NMR(400MHz,Chloroform-d)δ5.54–5.41(m,6H),5.41–5.28(m,6H),4.64(s,12H),4.36–4.06(m,18H),3.52(dt,J=9.6,6.8Hz,24H),3.08–2.50(m,24H),2.32(q,J=7.2Hz,12H),2.03(q,J=6.8Hz,12H),1.73(p,J=6.8Hz,12H),1.68–1.55(m,12H),1.40–1.28(m,24H),0.88(t,J=6.8Hz,18H).HRMS(ESI,m / z):[M+H] + calcd.ForC 102 H 187 N4O 30 ,1949.32582;found:1949.33204.

[0306] Compound L0469: 11H NMR (400 MHz, Chloroform-d) δ 4.26 (dd, J = 8.0, 3.6 Hz, 6H), 4.21–4.06 (m, 12H), 4.04 (t, J = 6.8 Hz, 12H), 3.15–2.40 (m, 24H), 2.33–2.24 (m, 6H), 1.74–1.48 (m, 36H), 1.47–1.33 (m, 36H), 1.31–1.20 (m, 96H), 0.85 (t, J = 6.8 Hz, 36H). HRMS (ESI, m / z): [M+H] + calcd. For C 144 H 271 N4O 30 , 2537.98312; found: 2537.98943.

[0307] Compound L0470: 1 1H NMR (400 MHz, Chloroform-d) δ 5.56–5.41 (m, 6H), 5.41–5.30 (m, 6H), 4.65 (s, 12H), 4.33–4.07 (m, 18H), 3.53 (dt, J = 10.0, 6.8 Hz, 24H), 3.10–2.47 (m, 24H), 2.32 (q, J = 7.2 Hz, 12H), 2.04 (q, J = 6.8 Hz, 12H), 1.93–1.67 (m, 18H), 1.67–1.58 (m, 12H), 1.38–1.28 (m, 24H), 0.93–0.81 (m, 18H). HRMS (ESI, m / z): [M+H] + calcd. For C 105 H 193 N4O 30 , 1991.37277; found: 1991.38136.

[0308] Compound L0471: 1 1H NMR (400 MHz, Chloroform-d) δ 4.23 (dd, J = 8.0, 3.2 Hz, 6H), 4.19–4.04 (m, 12H), 3.06–2.50 (m, 24H), 1.93–1.41 (m, 18H), 1.34–1.19 (m, 84H), 0.86 (t, J = 6.8 Hz, 18H). HRMS (ESI, m / z): [M+H] + calcd. For C 87 H 169 N4O 18,1558.24264; found:1558.24973.

[0309] Compound L0472: 1 H NMR(400MHz,Chloroform-d)δ4.26(dd,J=8.0,3.6Hz,6H),4.20–3.99(m,12H),3.41–3.08(m,6H),2.91–2.59(m,18 H),2.03–1.81(m,6H),1.62(p,J=6.8Hz,12H),1.35–1.20(m,108H),0.86(t,J=6.8Hz,18H).HRMS(ESI,m / z):[M+H] + calcd.For C 99 H 193 N4O 18 ,1727.43380; found:1727.43652.

[0310] Compound L0473: 1 H NMR(400MHz,Chloroform-d)δ7.08(t,J=6.0Hz,6H),4.08(dd,J=8.8,3.6Hz,6H),3.19(q,J=6.8Hz,12H),2.90(dd,J=13.6,4.0Hz,6H),2.7 7–2.56(m,12H),2.44–2.23(m,6H),1.50(dp,J=14.4,7.2,6.8Hz,18H),1.32–1.20(m,84H),0.85(t,J=6.8Hz,18H).HRMS(ESI,m / z):[M+3H] 3+ calcd.For C 87 H 177 N 10 O 12 ,518.11770;found:518.12216.

[0311] Compound L0475: 1¹H NMR (400 MHz, Chloroform-d) δ 4.63 (s, 12H), 4.24 (dd, J = 8.0, 3.6 Hz, 6H), 4.20–3.99 (m, 12H), 3.49 (t, J = 6.8 Hz, 24H), 3.31–2.99 (m, 6H), 2.89–2.69 (m, 14H), 2.68–2.56 (m, 4H), 1.99–1.76 (m, 6H), 1.75–1.44 (m, 36H), 1.43–1.24 (m, 60H), 0.86 (t, J = 6.8 Hz, 18H). HRMS (ESI, m / z): [M+H] + calcd. For C 105 H 205 N4O 30 , 2003.46667; found: 2003.47735.

[0312] Compound L0476: 1 ¹H NMR (400 MHz, Chloroform-d) δ 4.27 (dd, J = 8.4, 3.2 Hz, 6H), 4.22–3.99 (m, 24H), 3.45–3.01 (m, 6H), 2.93–2.72 (m, 14H), 2.72–2.57 (m, 4H), 2.34–2.25 (m, 6H), 2.01–1.86 (m, 6H), 1.71–1.51 (m, 36H), 1.48–1.34 (m, 36H), 1.32–1.22 (m, 96H), 0.86 (t, J = 6.8 Hz, 36H). HRMS (ESI, m / z): [M+2H] 2+ calcd. For C 147 H 278 N4O 30 , 1290.51868; found: 1290.52785.

[0313] Compound L0477: 1 ¹H NMR (400 MHz, Chloroform-d) δ 4.49–3.96 (m, 24H), 3.44–2.73 (m, 24H), 1.69–1.51 (m, 12H), 1.25 (d, J = 11.2 Hz, 84H), 0.86 (t, J = 6.8 Hz, 18H). HRMS (ESI, m / z): [M+H] + calcd. For C 84 H 163 N4O 18, 1516.19569; found: 1516.20294.

[0314] Compound L0478: 1 H NMR (400 MHz, Chloroform-d) δ 4.40–4.23 (m, 6H), 4.20–4.03 (m, 12H), 3.36–2.62 (m, 24H), 1.70–1.51 (m, 12H), 1.42–1.10 (m, 132H), 0.86 (t, J = 6.8 Hz, 18H). HRMS (ESI, m / z): [M+H] + calcd. For C 108 H 211 N4O 18 , 1853.57465; found: 1853.57832.

[0315] Compound L0479: 1 H NMR (400 MHz, Chloroform-d) δ 4.63 (q, J = 5.2 Hz, 6H), 4.25 (dd, J = 8.0, 3.2 Hz, 6H), 4.20–4.04 (m, 12H), 3.59–3.50 (m, 12H), 3.37 (dt, J = 9.2, 6.8 Hz, 12H), 3.08–2.53 (m, 24H), 1.71–1.48 (m, 36H), 1.39–1.23 (m, 78H), 0.86 (t, J = 6.8 Hz, 18H). HRMS (ESI, m / z): [M+H] + calcd. For C 108 H 211 N4O 30 , 2045.51362; found: 2045.51478.

[0316] Compound L0480: 1 H NMR (400 MHz, Chloroform-d) δ 4.52–4.37 (m, 6H), 3.42–3.22 (m, 12H), 3.11–2.85 (m, 20H), 2.84–2.53 (m, 22H), 1.73–1.45 (m, 18H), 1.34–1.18 (m, 108H), 0.86 (t, J = 6.8 Hz, 18H). HRMS (ESI, m / z): [M+H] + calcd. For C 105 H 211 N 10 O 12, 1805.62360; found: 1805.62826.

[0317] Compound L0481: 1 H NMR (400 MHz, Chloroform-d) δ 4.56–4.31 (m, 5H), 3.39–3.19 (m, 10H), 3.07–2.93 (m, 9H), 2.92–2.85 (m, 6H), 2.82–2.35 (m, 22H), 1.72–1.41 (m, 16H), 1.32–1.14 (m, 90H), 0.85 (t, J = 6.8 Hz, 15H). HRMS (ESI, m / z): [M+H] + calcd. For C 89 H 180 N9O 10 , m / z: 1535.38477; found: 1535.39418.

[0318] Compound L0482: 1 H NMR (400 MHz, Chloroform-d) δ 4.47 (t, J = 8.8 Hz, 6H), 3.40–3.22 (m, 12H), 3.10–2.94 (m, 14H), 2.94–2.85 (m, 10H), 2.85–2.56 (m, 18H), 1.60–1.43 (m, 12H), 1.33–1.16 (m, 108H), 0.86 (t, J = 6.8 Hz, 18H). HRMS (ESI, m / z): [M+H] + calcd. ForC 102 H 205 N 10 O 12 , 1763.57665; found: 1763.58230.

[0319] Compound L0483: 1 H NMR (400 MHz, Chloroform-d) δ 4.50–4.39 (m, 6H), 3.42–3.20 (m, 12H), 3.00 (s, 11H), 2.97–2.47 (m, 31H), 1.59–1.42 (m, 12H), 1.32–1.16 (m, 84H), 0.85 (t, J = 6.8 Hz, 18H). HRMS (ESI, m / z): [M+H] + calcd. For C 90 H 181 N 10 O 12,1594.38550; found:1594.39622.

[0320] Compound L0484: 1 H NMR(400MHz,Chloroform-d)δ4.50–4.31(m,6H),3.47–3.13(m,12H),3.00(s,10H),2.89(s ,8H),2.79–2.31(m,24H),1.87–0.91(m,102H),0.91–0.59(m,18H).HRMS(ESI,m / z):[M+H] + calcd.For C 93 H 187 N 10 O 12 ,1637.43580; found:1637.43913.

[0321] Compound L0485: 1 H NMR(400MHz,Chloroform-d)δ4.53–4.38(m,6H),3.40–3.21(m,12H),3.01(s,11H),2.96–2.47( m,31H),1.62–1.41(m,12H),1.34–1.14(m,60H),0.85(t,J=6.8Hz,18H).HRMS(ESI,m / z):[M+H] + calcd.For C 78 H 157 N 10 O 12 ,1426.19770; found:1426.20547.

[0322] Compound L0486: 1 H NMR(400MHz,Chloroform-d)δ4.48–4.36(m,6H),3.45–3.17(m,12H),3.09–2.95(m,11H),2.94–2.85(m,7H) ,2.84–2.36(m,24H),1.73–1.38(m,18H),1.34–1.13(m,60H),0.85(t,J=6.4Hz,18H).HRMS(ESI,m / z):[M+H] + calcd.For C 81 H 163 N 10 O 12 ,1468.24465; found:1468.25309.

[0323] Compound L0487: 1 H NMR(400MHz,Chloroform-d)δ4.50–4.39(m,6H),3.42–3.21(m,12H),3.06–2.97(m,11H),2.94–2.83(m,11H),2.81–2.46(m,20H),1.61–1.43(m,12H),1.36–1.10(m,132H),0.86(t,J=6.8Hz,18H).HRMS(ESI,m / z):[M+3H] 3+ calcd.ForC 114 H 231 N 10 O 12 ,644.59300;found:644.59279.

[0324] Compound L0488: 1 H NMR(400MHz,Chloroform-d)δ4.51–4.35(m,6H),3.40–3.23(m,12H),3.05–2.96(m,11H),2.94–2.86(m,7H),2.83–2.40(m,24H),1.71–1.44(m,18H),1.36–1.10(m,132H),0.85(t,J=6.8Hz,18H).HRMS(ESI,m / z):[M+H] + calcd.For C 117 H 235 N 10 O 12 ,1973.81140;found:1973.82239.

[0325] Compound L0489: 1 H NMR(400MHz,Chloroform-d)δ7.25–6.95(m,6H),4.16(d,J=7.6Hz,6H),4.05(t,J=6.8Hz,12H),3.34–3.14(m,12H),3.10–2.47(m,24H),2.34–2.25(m,6H),1.70–1.46(m,36H),1.46–1.19(m,132H),0.86(t,J=6.8Hz,36H).HRMS(ESI,m / z):[M+H] + calcd.For C 144 H 277 N 10 O24 ,2532.07903; found:2532.09648.

[0326] Compound L0490: 1 H NMR(400MHz,Chloroform-d)δ7.18(t,J=6.0Hz,6H),4.16(dd,J=8.8,3.2Hz,6H),4.03(t,J=6.8Hz,12H),3.28–3.15(m,J=6.8Hz,14H),3.04–2.87(m,8H),2 .86–2.58(m,14H),2.29(tt,J=9.2,5.6Hz,6H),1.93–1.70(m,6H),1.68–1.46 (m,36H),1.44–1.17(m,132H),0.85(t,J=6.8Hz,36H).HRMS(ESI,m / z):[M+H] + calcd.ForC 147 H 283 N 10 O 24 ,2574.12598; found:2574.14153.

[0327] Compound L0491: 1 H NMR(400MHz,Chloroform-d)δ7.59–7.27(m,6H),4.34–4.04(m,18H),3.61–3.43(m,J=7.6,6.8Hz,12H),3.03–2.51(m,24H),2 .38–2.28(m,6H),1.63–1.50(m,12H),1.48–1.37(m,12H),1.32–1.16(m,96H),0.85(t,J=6.8Hz,36H).HRMS(ESI,m / z):[M+H] + calcd.For C 120 H 229 N 10 O 24 ,2195.70343; found:2195.71164.

[0328] Compound L0492: 11H NMR (400 MHz, Chloroform-d) δ 7.57–7.29 (m, 6H), 4.25–4.05 (m, 18H), 3.48 (q, J=6.0 Hz, 12H), 3.09–2.60 (m, 24H), 2.36–2.26 (m, 6H), 1.93–1.67 (m, 6H), 1.61–1.50 (m, 12H), 1.47–1.37 (m, 12H), 1.30–1.16 (m, 96H), 0.85 (t, J=6.8 Hz, 36H). HRMS (ESI, m / z): [M+3H] 3+ calcd. For C 123 H 237 N 10 O 24 , 746.58831;found: 746.58730.

[0329] Compound L0493: 1 1H NMR (400 MHz, Chloroform-d) δ 7.26–7.08 (m, 6H), 4.26–4.10 (m, 6H), 4.06 (t, J=6.4 Hz, 12H), 3.36–3.19 (m, 12H), 3.18–2.39 (m, 24H), 2.34–2.24 (m, 6H), 1.71–1.49 (m, 36H), 1.47–1.37 (m, 12H), 1.33–1.21 (m, 96H), 0.86 (t, J=6.8 Hz, 36H). HRMS (ESI, m / z): [M+H] + calcd. For C 132 H 253 N 10 O 24 , 2363.89123;found: 2363.90057.

[0330] Compound L0494: 1 1H NMR (400 MHz, Chloroform-d) δ 7.12 (t, J=6.4 Hz, 6H), 4.22–3.97 (m, 18H), 3.26 (q, J=6.8 Hz, 12H), 3.01–2.87 (m, 5H), 2.86–2.48 (m, 13H), 2.38–2.15 (m, 12H), 1.71–1.45 (m, 42H), 1.44–1.37 (m, 12H), 1.32–1.20 (m, 96H), 0.85 (t, J=6.8 Hz, 36H). HRMS (ESI, m / z): [M+H] + calcd. For C135 H 259 N 10 O 24 ,2405.93818; found:2405.95028.

[0331] Compound L0495: 1 H NMR(400MHz,Chloroform-d)δ7.23–6.97(m,6H),4.25–4.09(m,6H),4.04(t,J=6.8Hz,12H),3.35–3.13(m,12H),3.06–2 .45(m,24H),2.36–2.24(m,6H),1.68–1.47(m,36H),1.46–1.16(m,156H),0.86(t,J=6.8Hz,36H).HRMS(ESI,m / z):[M+H] + calcd.For C 156 H 301 N 10 O 24 ,2700.26683; found:2700.29074.

[0332] Compound L0496: 1 H NMR(400MHz,Chloroform-d)δ7.20–6.91(m,6H),4.26–3.91(m,18H),3.33–3.14(m,12H),3.00–2.86(m,5H),2.84–2.4 7(m,13H),2.41–2.17(m,12H),1.69–1.45(m,42H),1.44–1.16(m,156H),0.85(t,J=6.8Hz,36H).HRMS(ESI,m / z):[M+H] + calcd.For C 159 H 307 N 10 O 24 ,2742.31378; found:2742.33817.

[0333] Compound L0497: 11H NMR (400 MHz, Chloroform-d) δ 7.60–7.28 (m, 6H), 4.45–3.95 (m, 18H), 3.66–3.41 (m, 12H), 3.20–2.43 (m, 24H), 2.41–2.28 (m, 6H), 1.65–1.52 (m, 12H), 1.50–1.39 (m, 12H), 1.35–1.18 (m, 120H), 0.87 (t, J=6.8 Hz, 36H). HRMS (ESI, m / z): [M+H] + calcd. For C 132 H 253 N 10 O 24 , 2363.89123; found: 2363.88239.

[0334] Compound L0498: 1 1H NMR (400 MHz, Chloroform-d) δ 7.49–7.26 (m, 6H), 4.31–4.00 (m, 18H), 3.62–3.40 (m, 12H), 3.07–2.55 (m, 20H), 2.44–2.24 (m, 10H), 1.66–1.37 (m, 30H), 1.34–1.16 (m, 120H), 0.86 (t, J=6.8 Hz, 36H). HRMS (ESI, m / z): [M+H] + calcd. For C 135 H 259 N 10 O 24 , 2405.93818; found: 2405.92726.

[0335] Compound L0499: 1 1H NMR (400 MHz, Chloroform-d) δ 7.25–7.05 (m, 6H), 4.25–4.09 (m, 6H), 4.06 (t, J=6.4 Hz, 12H), 3.38–3.17 (m, 12H), 3.04–2.45 (m, 24H), 2.34–2.24 (m, 6H), 1.74–1.48 (m, 36H), 1.47–1.37 (m, 12H), 1.33–1.15 (m, 120H), 0.86 (t, J=6.8 Hz, 36H). HRMS (ESI, m / z): [M+H] + calcd. For C 144 H 277 N 10 O 24,2532.07903; found:2532.07588.

[0336] Compound L0500: 1 H NMR(400MHz,Chloroform-d)δ7.11(t,J=6.0Hz,6H),4.27–3.96(m,18H),3.28(q,J=6.8Hz,12H),3.12–2.38(m,19H),2.37– 2.22(m,11H),1.70–1.47(m,40H),1.47–1.36(m,14H),1.34–1.18(m,120H),0.86(t,J=6.8Hz,36H).HRMS(ESI,m / z):[M+H] + calcd.For C 147 H 283 N 10 O 24 ,2574.12598; found:2574.12599.

[0337] Compound L0501: 1 H NMR(400MHz,Chloroform-d)δ7.90–7.59(m,6H),7.21–6.89(m,6H),5.84(s,6H),4.24–4.02(m,6H),3.51–3.24(m,24H),3.04–2.87(m,8H),2.8 1–2.46(m,16H),2.11–1.99(m,6H),1.59–1.45(m,12H),1.42–1.33(m,1 2H),1.30–1.15(m,96H),0.85(t,J=6.8Hz,36H).HRMS(ESI,m / z):[M+H]+ calcd.For C 120 H 235 N 16 O 18 ,2189.79933; found:2189.79622.

[0338] Compound L0502: 11H NMR (400 MHz, Chloroform-d) δ 7.80–7.61 (m, 6H), 7.17–6.89 (m, 6H), 5.81–5.38 (m, 5H), 4.17–3.98 (m, 6H), 3.51–3.22 (m, 24H), 2.94–2.79 (m, 6H), 2.76–2.39 (m, 16H), 2.33–2.23 (m, 2H), 2.10–1.98 (m, 6H), 1.65–1.42 (m, 18H), 1.41–1.32 (m, 12H), 1.31–1.14 (m, 96H), 0.84 (t, J=6.4 Hz, 36H). HRMS (ESI, m / z): [M+H]+ calcd. For C 123 H 241 N 16 O 18 , 2231.84628; found: 2231.84191.

[0339] Compound L0503: 1 1H NMR (400 MHz, Chloroform-d) δ 7.26–7.16 (m, 6H), 4.84 (p, J=6.4 Hz, 6H), 4.25–4.05 (m, 6H), 3.36–3.20 (m, 12H), 3.11–2.47 (m, 24H), 2.32 (t, J=7.6 Hz, 12H), 1.83 (p, J=7.2 Hz, 12H), 1.56–1.43 (m, 24H), 1.34–1.18 (m, 120H), 0.86 (t, J=6.8 Hz, 36H). HRMS (ESI, m / z): [M+H] + calcd. For C 138 H 265 N 10 O 24 , 2447.98513; found: 2447.98335.

[0340] Compound L0504: 11H NMR (400 MHz, Chloroform-d) δ 7.26–7.20 (m, 6H), 4.84 (p, J=6.4 Hz, 6H), 4.21–4.03 (m, 6H), 3.35–3.21 (m, 12H), 3.03–2.41 (m, 20H), 2.32 (t, J=7.6 Hz, 16H), 1.87–1.78 (m, 12H), 1.67–1.35 (m, 30H), 1.34–1.17 (m, 120H), 0.86 (t, J=6.8 Hz, 36H). HRMS (ESI, m / z): [M+H] + calcd. For C 141 H 271 N 10 O 24 , 2489.02873;found: 2489.04173.

[0341] Compound L0505: 1 1H NMR (400 MHz, Chloroform-d) δ 7.26–7.21 (m, 6H), 6.17–5.37 (m, 6H), 4.15 (dd, J=8.4, 3.0 Hz, 6H), 4.04 (t, J=6.8 Hz, 12H), 3.39–3.20 (m, 12H), 3.05–2.42 (m, 24H), 2.34 (t, J=7.6 Hz, 12H), 1.84 (p, J=7.2 Hz, 12H), 1.60 (p, J=6.8 Hz, 12H), 1.36–1.20 (m, 84H), 0.87 (t, J=6.8 Hz, 18H). HRMS (ESI, m / z): [M+H] + calcd. For C 108 H 205 N 10 O 24 , 2027.51563;found: 2027.51361.

[0342] Compound L0506: 1H NMR (400MHz, Chloroform-d) δ7.24 (d, J=6.4Hz, 6H), 4.09 (dd, J=8.8, 3.6Hz, 6H), 4.04 (t, J=6.8Hz, 12H), 3.37–3.17 (m, J=6.8Hz, 12H), 3.01–2.5 7(m,18H),2.33(t,J=7.6Hz,18H),1.83(p,J=7.2Hz,12H),1.67–1.44(m, 18H),1.34–1.19(m,84H),0.86(t,J=6.8Hz,18H).HRMS(ESI,m / z):[M+H] + calcd.For C 111 H 211 N 10 O 24 ,2069.56258; found:2069.55766.

[0343] Example 4: Preparation of Nucleic Acid Nanoparticle Complex

[0344] Take a nucleic acid drug stock solution (wherein the nucleic acid can be FLuc mRNA, EGFP pDNA, EGFP siRNA, SpikemRNA) and dilute it with a buffer solution to a nucleic acid concentration of 0.04 mg / mL (the buffer can be: PBS buffer with a pH value of 3 to 6 and a concentration of 1 to 200 mM, citric acid-sodium citrate buffer, citric acid-disodium hydrogen phosphate buffer, HEPES buffer, sodium acetate buffer, Tris buffer, preferably pH = 4, PBS buffer with a concentration of 10 mM, 20 mM, 50 mM, citric acid-sodium citrate buffer; In this embodiment, a citric acid-sodium citrate buffer with a pH of 4 and a concentration of 50 mM is used) as the aqueous phase.

[0345] According to the prescriptions described in each embodiment (such as Table 1 of Example 5, Table 2 of Example 6, Table 4 of Example 7, Table 5 of Example 8, etc.), nucleic acid nanoparticle complexes are prepared, the required PEG derivatives, phospholipids, cholesterol analogs and lipid compounds are taken out of the refrigerator and balanced to room temperature, PEG derivatives, phospholipids, cholesterol analogs and lipid compounds are weighed and dissolved in ethanol (PEG derivatives are dissolved in ethanol, and the dissolution concentration range is: 1 mg / mL~10 mg / mL; phospholipids are dissolved in ethanol, and the dissolution concentration range is: 1 mg / mL~20 mg / mL; cholesterol analogs are dissolved in ethanol, and the dissolution concentration range is: 1 mg / mL~20 mg / mL; lipid compounds are dissolved in ethanol, and the dissolution concentration range is: 1 mg / mL~30 mg / mL), ultrasonic dispersion is used to assist dissolution, and the dissolved PEG derivatives, phospholipids, cholesterol analogs and lipid compounds are mixed according to the prescriptions described in each embodiment (such as Table 1 of Example 5, Table 2 of Example 6, Table 4 of Example 7, Table 5 of Example 8, etc.). Table 1 of Example 5, Table 2 of Example 6, Table 4 of Example 7, Table 5 of Example 8, etc.) are taken in corresponding volumes of solution and mixed, and then an appropriate amount of ethanol is added to mix (the amount of ethanol added is adaptively adjusted according to the component ratio of each prescription nucleic acid nanoparticle complex and the ratio of the aqueous phase and the organic phase in the subsequent operation), and an ethanol solution containing PEG derivatives, phospholipids, cholesterol analogs and lipid compounds is prepared as the organic phase. The volume ratio of the aqueous phase to the organic phase is 3:1, and the aqueous phase and the organic phase are quickly mixed using a nanoparticle preparation instrument at a flow rate ratio of 3:1. The ethanol and water in the mixed solution are removed by dialysis or ultrafiltration, and nuclease-free water is added to make the nucleic acid concentration 0.04 mg / mL. Finally, the nucleic acid nanoparticle complex prescriptions described in each embodiment (such as Table 1 of Example 5, Table 2 of Example 6, Table 4 of Example 7, Table 5 of Example 8, etc.) are obtained, and stored at 2-8°C for use.

[0346] The formulations prepared using commercially available ionizable lipid molecules SM-102 (CAS: 2089251-47-6) and ALC-0315 (CAS: 2036272-55-4) were used as controls.

[0347] Example 5: Characterization of the nucleic acid nanoparticle complex of the present invention

[0348] Using FLuc-mRNA as the model mRNA, the nucleic acid nanoparticle complexes of Table 1 were prepared according to the preparation method described in Example 4, and the dynamic light scattering particle size (size), surface potential (Zeta Potential) and polydispersity (PDI (polydispersity index)) of the nucleic acid nanoparticle complexes were tested at 25°C using a Malvern Zetasizer Nano ZSE.

[0349] Table 1: Characterization of nucleic acid nanoparticle complexes

[0350]

[0351]

[0352]

[0353]

[0354] Note: The nitrogen-to-phosphorus ratio in Table 1 represents the ratio of the molar amount of ionizable nitrogen atoms in the lipid compound of the present invention to the molar amount of phosphorus atoms in nucleic acids.

[0355] The nitrogen-phosphorus ratio of the lipid compound to the nucleic acid in Table 1 represents the ratio of the molar amount of ionizable nitrogen atoms in the lipid compound (i.e., the compound provided by the present invention, such as at least one of compounds L0461-L0506, or ALC-0315 or SM-102) in the nucleic acid nanoparticle complex to the molar amount of phosphorus atoms in the nucleic acid.

[0356] The results are shown in Table 1, which show that the average particle size of the nucleic acid nanoparticle complex of the present invention ranges from 70 nm to 268 nm, the PDI is small, the particle size uniformity is good, and the surface charge of the nanocomplex is between -9 mV and +17 mV.

[0357] Example 6: In vitro cell transfection experiment of nucleic acid nanoparticle complex

[0358] The experiment of silencing gene expression by in vitro transfection of HeLa-EGFP cells (polyclonal cell line stably expressing EGFP fluorescent protein) with nucleic acid nanoparticle complexes encapsulating EGFP-siRNA (using EGFP-siRNA as model siRNA):

[0359] The cell suspension in logarithmic growth phase was diluted to 1×10 5 The density of cells per well was divided into 24-well plates and placed in a 37°C, 5% CO2 incubator for static culture. After 24 hours, EGFP-siRNA was taken and the nucleic acid nanoparticle complexes shown in Table 2 were prepared according to the preparation method described in Example 4, and then the nucleic acid nanoparticle complex mixture was diluted with opti-MEM. After standing, nucleic acid nanoparticle complexes containing 160ng EGFP-siRNA were added to each well, and each sample was repeated for 3 wells. 4 hours after administration, the culture medium in the 96-well plate was replaced with complete culture medium. The culture was continued for 18 hours, the cells were digested and collected, the fluorescence intensity of the FITC channel of live cells in each well was detected by flow cytometry, and the geometric mean of the fluorescence intensity of EGFP-positive cells in the duplicate wells was calculated. The siRNA silencing efficiency (i.e., the percentage reduction in the average fluorescence intensity of the cells) was calculated as follows:

[0360] siRNA silencing efficiency (%) = (geometric mean fluorescence intensity of cells not transfected with nucleic acid nanoparticle complexes - geometric mean fluorescence intensity of cells transfected with nucleic acid nanoparticle complexes) / geometric mean fluorescence intensity of cells not transfected with nucleic acid nanoparticle complexes × 100%

[0361] Table 2: Silencing efficiency of EGFP-siRNA-loaded nucleic acid nanoparticle complexes delivered to Hela-EGFP cells

[0362]

[0363] Note: The nitrogen-phosphorus ratio in Table 2 represents the ratio of the molar amount of ionizable nitrogen atoms in the lipid compound of the present invention to the molar amount of phosphorus atoms in nucleic acids.

[0364] The results are shown in Table 2. Conclusion: The results show that the nucleic acid-lipid compound encapsulating EGFP-siRNA showed good gene silencing effect in cell transfection, among which Rp.74-Rp.83 had a silencing efficiency of more than 70% in delivering siRNA in cells, which was better than the control group Rp.84 and Lipo2000.

[0365] Example 7: Small animal fluorescence imaging to detect transfection of nucleic acid nanoparticle complexes in mice

[0366] 7.1. Effect of Nucleic Acid Lipid Nanoparticles on FLuc-mRNA Delivery in Mice

[0367] Three BALB / c mice were used in each group. FLuc-mRNA was used as the model mRNA. The nucleic acid nanoparticle complex containing FLuc-mRNA in Table 3 was prepared according to the preparation method described in Example 4. After the preparation was completed, the preparation was taken for intramuscular injection (IM) or intravenous injection (IV) or intraperitoneal injection (IP) or subcutaneous injection (IH). About 75 μL of the nucleic acid nanoparticle complex prescription containing 3 μg FLuc-mRNA was injected into each mouse using an insulin needle, for a total of 3 mice. When the administration method was intravenous injection, the injection site was the mouse tail vein. When the administration method was intraperitoneal injection, the injection site was the mouse abdominal cavity. When the administration method was intramuscular injection, the injection site was the mouse thigh muscle. When the administration method was subcutaneous injection, the injection site was subcutaneous on the back of the mouse.

[0368] In vivo imaging (PerkinElmer Inc., IVIS LuminaⅢ) is performed after a certain period of time after injection. Intravenous injection is usually detected 3 hours after administration, intraperitoneal injection is usually detected 6 hours after administration, intramuscular injection is usually detected 24 hours after administration, and subcutaneous injection is usually detected 24 hours after administration.

[0369] Take an appropriate amount of substrate D-Luciferin (D-fluorescein), dilute it with PBS to prepare a solution with a concentration of 15 mg / mL, keep it away from light, and inject 200 μL of 15 mg / mL D-Luciferin working solution intraperitoneally into each mouse 10-15 minutes before imaging. Use a small animal in vivo imaging system (PerkinElmer, IVIS Lumina SeriesⅢ) to perform whole-body in vivo imaging bioluminescence image detection on the mice. Take bioluminescent images of the mice and count the luminescent signals.

[0370] Table 3: Delivery effect of FLuc-mRNA-loaded nucleic acid nanoparticle complexes in mice

[0371]

[0372]

[0373]

[0374]

[0375]

[0376] Remark:

[0377] (1) The nitrogen-to-phosphorus ratio in Table 3 represents the ratio of the molar amount of ionizable nitrogen atoms in the lipid compound of the present invention to the molar amount of phosphorus atoms in nucleic acids.

[0378] (2) IV means intravenous injection; IM means intramuscular injection.

[0379] Results: The results are shown in Table 3. The nucleic acid nanoparticle complex formulations in the experimental group showed luciferase expression in whole-body in vivo imaging. The greater the fluorescence intensity, the more luciferase was expressed.

[0380] Conclusion: The nucleic acid nanoparticle complexes of each experimental group encapsulating FLuc-mRNA have good luciferase expression in mice.

[0381] As shown in Table 3, in the intramuscular injection experimental group, all the prescriptions were effectively expressed in mice after administration. In the intravenous injection experimental group, all the prescriptions were effectively expressed in mice after administration. The expression of luciferase in prescriptions Rp.02, Rp.07, Rp.13, Rp.15, Rp.18, Rp.23, Rp.24, Rp.53, Rp.54 and Rp.65 was significantly higher than that in prescription Rp.72 prepared by commercially available ionizable lipid SM-102 and prescription Rp.73 prepared by ALC-0315.

[0382] 7.2. Effect of Nucleic Acid Lipid Nanoparticles on FLuc-circRNA Delivery in Mice

[0383] Three BALB / c mice were used in each group. FLuc-circRNA (manufacturer: Hongene Biotech Corporation) was used as the model RNA. The nucleic acid nanoparticle complex containing FLuc-circRNA in Table 4 was prepared according to the preparation method described in Example 4. After the preparation was completed, the preparation was injected intramuscularly (into the rectus femoris muscle of the mouse thigh) or intravenously (into the tail vein of the mouse) or intraperitoneally or subcutaneously (under the back skin), and each mouse was injected with about 75 μL. After a certain period of injection, in vivo imaging (PerkinElmer Co., Ltd., IVIS LuminaⅢ) was performed. 200 μL of 15 mg / mL D-Luciferin (D-fluorescein) working solution was injected intraperitoneally 10-15 minutes before imaging, and imaging analysis was performed using an in vivo imager.

[0384] Table 4: Delivery effect of FLuc-circRNA-loaded nucleic acid nanoparticle complexes in mice

[0385]

[0386] Note: The nitrogen-to-phosphorus ratio in Table 4 represents the ratio of the molar amount of ionizable nitrogen atoms in the lipid compound of the present invention to the molar amount of phosphorus atoms in nucleic acids.

[0387] Results: The results are shown in Table 4. The nucleic acid nanoparticle complex formulations in the experimental group showed luciferase expression in whole-body in vivo imaging. The greater the fluorescence intensity, the more luciferase was expressed.

[0388] Conclusion: The nucleic acid nanoparticle complexes of each experimental group encapsulating FLuc-circRNA have good luciferase expression in mice.

[0389] As shown in Table 4, in the intramuscular injection experimental group, all the prescriptions were effectively expressed in mice after administration. In the intravenous injection experimental group, all the prescriptions were effectively expressed in mice after administration. The expression of luciferase in prescriptions Rp.85, Rp.86 and Rp.87 was significantly higher than that in prescription Rp.89 prepared by commercially available ionizable lipid SM-102, and the expression of luciferase in prescriptions Rp.85 and Rp.86 was significantly higher than that in prescription Rp.88 prepared by commercially available ionizable lipid ALC-0315.

[0390] Example 8: Evaluation of humoral immune effects of nucleic acid nanoparticle complexes in mice

[0391] The SARS-CoV-2 S-mRNA was used as a model mRNA. The SARS-CoV-2 S-mRNA was provided by Hongene Biotech Corporation. The nucleotide sequence of the SARS-CoV-2 S-mRNA (cap1 structure, N1-me-pseudo U modified) is shown in the S-mRNA in the sequence list.

[0392] The specific information of S-mRNA stock solution is as follows:

[0393] Product Name: COVID-19 Spike Protein, Full Length-mRNA;

[0394] Product description: 4088 nucleotides in length;

[0395] Modifications: Fully substituted with N1-Me-pseudo UTP;

[0396] Concentration: 1.0 mg / mL;

[0397] Storage environment: 1mM sodium citrate, pH 6.4;

[0398] Storage requirements: -40℃ or below.

[0399] Experimental process:

[0400] Table 5: In vivo immunization prescription of nucleic acid nanoparticle complex loaded with S-mRNA in mice

[0401]

[0402] 8.1. In vivo immune experiment:

[0403] The lipid nanoparticles containing nucleic acid drugs were prepared according to the method shown in Example 4, and the Delta Spike full length mRNA (Shanghai Zhaowei Technology Development Co., Ltd.) was used as the formulation and then administered. Each mouse was administered a dose of 5 μg, and an equal volume of PBS buffer was used as the blank control group, and 5 μg naked S-mRNA was used as the negative control group. On the 14th day after the first immunization, whole blood was collected from the mice by bleeding from the outer canthus. After blood collection, the drug was repeatedly administered for secondary immunization. On the 14th day after the second immunization, whole blood was collected from the mice by bleeding from the outer canthus. The whole blood was centrifuged at 5000 rcf for 5 minutes, and the supernatant was centrifuged at 10000 rcf for 5 minutes to obtain the serum, which was divided into continuous tubes and stored in a -20°C refrigerator.

[0404] 8.2. Elisa or Elisa titer test to detect specific antibody levels:

[0405] 8.2.1 Coating: Add 100 μL of 0.2 μg / 100 μL Delta-S protein (Suzhou Nearshore Protein Technology Co., Ltd.) dilution to each well and place in a 4°C refrigerator for 12 h.

[0406] 8.2.2. Washing: Add 200 μL of PBST (PBS buffer solution with a pH of 7.4 containing 0.05% Tween-20) to each well and wash three times.

[0407] 8.2.3. Blocking: Add 200 μL of 5% (w / v) BSA-PBS solution (BSA bovine serum albumin, Beijing Bioson Biotechnology Co., Ltd.) to each well and shake at 50 rcf for 2 h at room temperature using a shaker.

[0408] 8.2.4. Washing: Add 200 μL of PBST to each well for washing.

[0409] 8.2.5. Add samples: add 100 μL serum diluted 200 times with PBS (i.e. 0.5 μL serum) to each well (serum for ELISA titer experiment was diluted 1000 times, 10000 times, 100000 times, 1000000 times), and shake at 50 rcf for 2 h at room temperature using a shaker.

[0410] 8.2.6. Washing: Add 200 μL of PBST to each well and wash three times.

[0411] 8.2.7. Add detection antibody: Add 100 μL of 1000-fold diluted HRP-labeled goat anti-mouse IgG detection antibody (i.e., 0.1 μL antibody stock solution) (Sangon Biotechnology (Shanghai) Co., Ltd.) to each well and shake at 50 rcf for 1 h at room temperature on a shaker.

[0412] 8.2.8. Washing: Add 200 μL of PBST to each well and wash three times.

[0413] 8.2.9. Add TMB (Beijing Solebow Biotechnology Co., Ltd.): Add 50 μL of TMB mixture with a volume ratio of 1:1 of solution A: solution B to each well and react for about 5 minutes.

[0414] 8.2.10. Add phosphoric acid (Aladdin Reagent (Shanghai) Co., Ltd.): Add 50 μL of 1 mol / L phosphoric acid to each well to terminate the reaction.

[0415] 8.2.11. Detection: Use a multifunctional ELISA reader for detection.

[0416] Serum IgG antibody level results: Figure 1 shown.

[0417] Conclusion: The results showed that the OD values ​​of prescriptions Rp.91, Rp.92, Rp.93, and Rp.94 after the second immunization were significantly higher than those of the blank control group and the naked mRNA negative control group, causing significant immune responses, suggesting that these prescription nucleic acid nanoparticle complexes have strong serum conversion efficiency and humoral immune activation function.

[0418] Serum IgG antibody titer results: Figure 2 shown.

[0419] Conclusion: The results showed that the serum of prescriptions Rp.91 and Rp.93 after the second immunization was diluted 1×10 6 The OD values ​​after treatment were significantly higher than those of the blank control group and the naked mRNA negative control group, and the OD values ​​were lower than those of the commercial ionizable cationic lipid molecule ALC-0315 prescription Rp.90, indicating that the immune effects of prescriptions Rp.91 and Rp.93 were weaker than those of the commercial ionizable cationic lipid molecule ALC-0315 prescription Rp.90, suggesting that although these prescription nucleic acid nanoparticle complexes caused weaker immune responses, they had better functions in mRNA delivery and expression.

[0420] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0421] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A lipid compound, the structure of which is shown in formula A, in, Each n is independently selected from any positive integer from 1 to 20, and each m is independently selected from any positive integer from 1 to 20; R 1 , R 2 and R 3 are each independently selected from hydrogen, substituted or unsubstituted C 1-20 Alkyl, substituted or unsubstituted C 2-20 Alkenyl, substituted or unsubstituted C 2-20 Alkynyl, substituted or unsubstituted C 2-20 Heteroalkyl, wherein the substituted or unsubstituted C 1-20 Alkyl, substituted or unsubstituted C 2-20 Alkenyl, substituted or unsubstituted C 2-20 Alkynyl or substituted or unsubstituted C 2-20 The substitution in heteroalkyl independently means that at least one hydrogen atom is replaced by 1-5 halogen, cyano, -OR 4 、-SR 4 、N(R 4 )2、-N(R 4 )3 + , oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C 1-6 substituted with haloalkyl; Each R 4 are independently selected from hydrogen, substituted or unsubstituted C 1-12 Alkyl, substituted or unsubstituted C 2-12 Alkenyl or substituted or unsubstituted C 2-12 Alkynyl; wherein each R 4 Each substituted or unsubstituted C 1-12 Alkyl, substituted or unsubstituted C 2-12 Alkenyl or substituted or unsubstituted C 2-12 Substitution in the alkynyl group independently means that at least one hydrogen atom is replaced by 1 to 5 halogen, cyano, -OH, -SR 5 、N(R 5 )2 or -N(R 5 )3 + or at least 2 hydrogen atoms are replaced by =O; Each R 5 are independently selected from hydrogen, substituted or unsubstituted C 1-12 Alkyl, substituted or unsubstituted C 2-12 Alkenyl or substituted or unsubstituted C 2-12 Alkynyl; wherein each R 5 Each substituted or unsubstituted C 1-12 Alkyl, substituted or unsubstituted C 2-12 Alkenyl or substituted or unsubstituted C 2-12 Substitution in the alkynyl group independently means that at least one hydrogen atom is replaced by 1 to 5 halogen, cyano, -OH, -SH, NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + or at least an even number of hydrogen atoms are replaced by =O; Each L is independently selected from C 1-10 Alkylene or C 3-10 heteroalkylene; Each Y is independently selected from -O- or -NR 6 -; Each R 6 are independently selected from hydrogen, substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl or substituted or unsubstituted C 1-6 haloalkyl; wherein each R 6 Each substituted or unsubstituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl or substituted or unsubstituted C 1-6 The substitution in haloalkyl independently means that at least one hydrogen atom is replaced by 1-5 halogen, cyano, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + , C 1-6 Alkoxy or C 1-6 or at least 2 hydrogen atoms are replaced by =O; Each R is independently selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 2-20 Alkynyl, -Z 1 -heterocyclic group, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkynyl, -Z 1 -C 1-6 Alkylene-Z-heterocyclyl, -Z 1 -C 2-6 Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 Alkenyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 Alkynyl, -Z 1 -C 2-6 Alkynyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkynyl-ZC 2-20 Alkenyl or -Z 1 -C 2-6 Alkynyl-ZC 2-20 Alkynyl; Each Z is independently selected from a carbon-carbon single bond, -O-, -O-CH2-O-, -O-CH2(CH3)-O-, -OC(O)-, -NR 4 C(O)-, -C(O)O-, -NR 4 -, -S-, -SS-, -C(O)-, -C(O)NR 4 -、-S(O)-、-S(O)2-、-NR 4 C(O)O-、-NR 4 C(O)NR 4 -、-NR 4 S(O)- or -S(O)2NR 4 -; Each Z 1 are independently selected from carbon-carbon single bonds, -O-, -NR 4 -, -S-, -SS-, -C(O)-, -C(O)O-, -C(O)NR 4 -、-S(O)-、-S(O)2-、-NR 4 C(O)-、-NR 4 C(O)O-、-NR 4 C(O)NR 4 -、-NR 4 S(O)- or -S(O)2NR 4 -; Each R 4 are independently selected from H or C 1-6 alkyl; In the compound represented by formula A, each The linear moiety contains at least 6 linear atoms or contains 6-20 linear atoms.

2. The lipid compound according to claim 1, wherein R 1 , R 2 and R 3 are independently selected from hydrogen, substituted or unsubstituted C 1-20 alkyl, Each R 6 are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl; Each R is independently selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1 -C 2-6 Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 Alkenyl.

3. The lipid compound according to any one of claims 1-2, wherein n is selected from any positive integer in the range of 1-20, and m is selected from any positive integer in the range of 1-20; R 1 , R 2 and R 3 are independently selected from hydrogen, unsubstituted C 1-20 Alkyl or R 6 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl; Each Y is independently selected from -O- or -NR 6 -; R is selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1 -C 2-6 Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 alkenyl; Each Z is independently selected from a carbon-carbon single bond, -O-, -O-CH2-O-, -O-CH2(CH3)-O-, -OC(O)-, -NR 4 C(O)-, -C(O)O-; Each Z 1 Independently selected from -O-, -NR 4 -; Each R 4 are independently selected from H or C 1-6 alkyl.

4. The lipid compound according to any one of claims 1 to 3, wherein the compound represented by formula A comprises compound B, 5. The lipid compound according to any one of claims 1 to 4, wherein the compound represented by formula B comprises: Compound C, Compound D, 6. The lipid compound according to claim 5, wherein in the compound C, n is selected from any positive integer in the range of 1-10, m is selected from any positive integer in the range of 1-20; R is selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1 -C 2-6 Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 alkenyl; In the compound C, each Z is independently selected from a carbon-carbon single bond, -O-, -O-CH2-O-, -O-CH2(CH3)-O-, -OC(O)-, -NR 4 C(O)-, -C(O)O-; In the compound C, each Z 1 Independently selected from -O-, -NR 4 -; In the compound C, each R 4 are independently selected from H or C 1-6 alkyl; In the compound D, R 6 is selected from hydrogen or unsubstituted C 1-3 Alkyl; n is selected from any positive integer from 1 to 10, m is selected from any positive integer from 1 to 20; R is selected from hydrogen, -Z 1 -C 1-20 Alkyl, -Z 1 -C 2-20 Alkenyl, -Z 1 -C 1-6 Alkylene-ZC 1-20 Alkyl, -Z 1 -C 1-6 Alkylene-ZC 2-20 Alkenyl, -Z 1 -C 2-6 Alkenyl-ZC 1-20 Alkyl, -Z 1 -C 2-6 Alkenyl-ZC 2-20 alkenyl; In the compound D, each Z is independently selected from a carbon-carbon single bond, -O-, -O-CH2-O-, -O-CH2(CH3)-O-, -OC(O)-, -NR 4 C(O)-, -C(O)O-; In the compound D, each Z 1 Independently selected from -O-, -NR 4 -; In the compound D, each R 4 are independently selected from H or C 1-6 alkyl.

7. The lipid compound according to claim 6, wherein the compound C is selected from the group consisting of compound L0461, compound L0464, compound L0465, compound L0467, compound L0468, compound L0469, compound L0470, compound L0471, compound L0472, compound L0475, compound L0476, compound L0477, compound L0478, compound L0479, compound L0491, compound L0492, compound L0497, and compound L0498; The compound D is selected from the group consisting of compounds L0462, L0463, L0473, L0474, L0480, L0481, L0482, L0483, L0484, L0485, L0486, L0487, L0488, L0489, L0490, L0493, L0494, L0495, L0496, L0499, L0500, L0501, L0502, L0503, L0504, L0505, and L0506; 8. A lipid compound nanoparticle, characterized in that: Comprising the lipid compound according to any one of claims 1 to 7 and auxiliary materials; or comprising the lipid compound according to any one of claims 1 to 7, nucleic acid and auxiliary materials; Optionally, the auxiliary material is selected from at least one of: PEG derivatives, lipids, lipidoids, alcohols, sugars or inorganic salts; Optionally, the PEG derivative is selected from at least one of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, PEG-modified stearic acid, and PEG-modified phosphatidylserine; Optionally, the PEG derivative comprises 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)], dilauroylphosphatidylethanolamine-polyethylene glycol, dimyristoylphosphatidylethanolamine-polyethylene glycol, dipalmitoylphosphatidylcholine polyethylene glycol, dipalmitoylphosphatidylethanolamine-polyethylene glycol, PEG-distearylglycerol, PEG-dipalmitoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglyceramide, PEG-dipalmitoylphosphatidylethanolamine or PEG-1,2-dimyristyloxypropyl-3-amine; Optionally, the PEG derivative includes at least one of DMG-PEG2000, mPEG-DSPE, mPEG-STA, mPEG-PS, mPEG-DMPE, mPEG-DPPE, ALC-0159, mPEG2k-DMPE, and DSPE-PEG5000; Optionally, the lipid comprises a phospholipid or a sterol; Optionally, the phospholipids include at least one selected from lecithin, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-diondecanoyl-sn-glycero-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; Optionally, the sterol comprises at least one of cholesterol, lanosterol, 5α-cholestane-3β-ol, coprostanol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid or α-tocopherol.

9. The lipid compound nanoparticle according to claim 8, wherein the lipid compound nanoparticle comprises the lipid compound according to any one of claims 1 to 7 and an auxiliary material; or comprises the lipid compound according to any one of claims 1 to 7, a nucleic acid and an auxiliary material; The auxiliary materials are PEG derivatives and lipids; the lipids are selected from phospholipids or sterols; Optionally, the phospholipids include at least one selected from phosphatidylcholine (PC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diondecanoyl-sn-glycero-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; Optionally, the sterol comprises at least one of cholesterol, lanosterol, 5α-cholestane-3β-ol, coprostanol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid or α-tocopherol.

10. The lipid compound nanoparticles according to any one of claims 8 to 9, wherein the content of the lipid compound according to any one of claims 1 to 7 is 20.0 mol% to 75.0 mol% calculated based on the total molar amount of each component in the lipid compound nanoparticles; and / or The content of the PEG derivative is 0.5 mol%-10 mol% calculated based on the total molar amount of each component in the lipid compound nanoparticles; and / or Calculated based on the total molar amount of each component in the lipid compound nanoparticles, the content of the phospholipid is 4.0 mol%-20.0 mol%; and / or Calculated based on the total molar amount of each component in the lipid compound nanoparticles, the content of the sterol is 18.0 mol%-68.5 mol%; or the content of the sterol is 20.0 mol%-68.5 mol%; and / or The molar ratio of PEG derivative: phospholipid: sterol: lipid compound according to any one of claims 1 to 7 in the lipid compound nanoparticles is (0.5-10.0): (4.0-20.0): (18.0-68.5): (20.0-75.0); and / or The molar ratio of PEG derivative: phospholipid: sterol: lipid compound according to any one of claims 1 to 7 in the lipid compound nanoparticles is (0.5-10.0): (4.0-20.0): (20.0-68.5): (20.0-75.0); and / or The molar ratio of PEG derivative: phospholipid: sterol: lipid compound according to any one of claims 1 to 7 in the lipid compound nanoparticles is 2.50:16.00:33.00:48.50, 6.00:16.00:29.50:48.50, 2.50:4.00:45.00:48.50, 0.95:7.58:26.47:65.00, 1.50:11.50:38.50:48.50, 1.58:16.84:18.42:63.16, 10.00:4.00:56.00:30.00, 2.32:6.20:45.00:46.48:0 .50:4.00:65.50:30.00, 2.50:11.50:56.00:30.00, 2.00:5.00:68.00:25.00, 3.00:4.00:18.00:75.00, 2.00:20.00:43.00:35.00, 1.50:10.00:68.50:20.00, 2.50:4.00:63.50:30.00, 1.50:16.00:22.50:60.00, 1.50:4.00:64.50:30.00 or 1.40:11.15:38.95:48.50; and / or The molar ratio of PEG derivative: phospholipid: sterol: lipid compound according to any one of claims 1 to 7 in the lipid compound nanoparticles is (0.5-2.5): (7.58-16.0): (29.5-56.0): (35.0-48.5); and / or The molar ratio of PEG derivative: phospholipid: sterol: lipid compound according to any one of claims 1 to 7 in the lipid compound nanoparticles is 0.50:4.00:65.50:30.00, 1.50:11.50:38.50:48.50 or 1.40:11.15:38.95:48.50; and / or The PEG derivative is selected from DMG-PEG2000, mPEG-DMPE, mPEG-DSPE, ALC-0159, mPEG-DPPE, mPEG-STA, mPEG-PS, mPEG2k-DMPE, DSPE-PEG5000; and / or The phospholipids include at least one of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), phosphatidylcholine (PC), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); and / or The sterol includes at least one of cholesterol (Chol) and lanosterol (Lanosterol).

11. A nucleic acid nanoparticle complex, characterized in that: Comprising nucleic acid and lipid compound nanoparticles according to any one of claims 8 to 10; Optionally, the ratio of the molar amount of ionizable nitrogen atoms in the compound in the lipid compound nanoparticles according to any one of claims 8 to 10 to the molar amount of phosphorus atoms in the nucleic acid in the nucleic acid nanoparticle complex is 6 to 65; Optionally, the ratio of the molar amount of ionizable nitrogen atoms in the lipid compound to the molar amount of phosphorus atoms in the nucleic acid in the lipid compound nanoparticles of any one of claims 8 to 10 in the nucleic acid-nanoparticle complex is 6, 7, 8, 9, 10, 11, 12, 13, 13.5, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 or 65; Optionally, the nucleic acid is deoxyribonucleic acid (DNA) or ribonucleic acid (RNA); Optionally, the ribonucleic acid (RNA) includes at least one of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), self-replicating RNA (saRNA), small hairpin RNA (shRNA), circular RNA (circRNA), messenger RNA (mRNA), or a combination thereof; Optionally, the average particle size of the lipid compound complex is 70nm-300nm; and / or Optionally, the lipid compound complex has a polydispersity coefficient of ≤ 0.

30.

12. A pharmaceutical composition, characterized in that Comprising the lipid compound nanoparticles according to claims 8-10 or the nucleic acid nanoparticle complex according to claim 11, and pharmaceutically acceptable excipients; Optionally, the dosage form of the pharmaceutical composition includes injection, suppository, eye drop, tablet, capsule, suspension or inhalant.

13. Use of the lipid compound according to any one of claims 1 to 7, the lipid compound nanoparticles according to claims 8 to 10, the nucleic acid nanoparticle complex according to claim 11 or the pharmaceutical composition according to claim 12 in the preparation of a product for in vivo delivery of nucleic acids.

Citation Information

Patent Citations

  • Amine-containing transfection reagents and methods for making and using same

    CN108358812A

  • Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids

    CN109414408A

  • Amine-containing transfection reagents and methods for making and using same

    CN113214102A

  • Lipid compound, lipid carrier containing lipid compound, nucleic acid lipid nanoparticle composition and pharmaceutical preparation

    CN113264842A

  • Unsaturated dendrimer compositions, related formulations, and methods of use thereof

    CN117157101A